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ABSTRACT
In the continuing search for effective treatments for cancer, the emerging model is the
combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel
growth. However, the implementation of this strategy has faced two major obstacles. First, the
long-term shutdown of tumor blood vessels by the anti-angiogenesis agent can prevent the tumor
from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood
supply drives the formation of intra-tumoral hypoxia, or a lack of oxygen, which has been
correlated with increased tumor invasiveness and resistance to chemotherapy.
In this thesis we report the disease-driven engineering of a drug delivery system, a
'nanocell', which overcomes these barriers unique to solid tumors. The nanocell comprises a
nuclear nanoparticle encapsulated within a lipid membrane and is preferentially taken up by the
tumor. The nanocell delivers a temporal release of two drugs within the tumor core: the outer
lipid envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner
nanoparticle, which is trapped inside the tumor, then releases a chemotherapy agent. This focal
release within the tumor targets cells most at risk for hypoxia and results in improved therapeutic
index with reduced toxicity. The technology can be extended to additional agents, so as to target
multiple signaling pathways or distinct tumor compartments, enabling the model of an
'integrative' approach in cancer therapy.
In the second part of the thesis we report new tools for the optimization of nanocell
formulations. We present a new, three-dimensional, voxel-based computational model for Monte
Carlo simulations of nanoparticle delivery systems that enables direct investigation of the entire
vehicle during particle degradation and drug release. Use of this model in combination with
emerging mechanistic understandings of nanoparticle drug release will facilitate optimization of
nanocell combination therapy release profiles. We additionally report the generation and
characterization of a set of carbohydrate-based chemotherapeutic agents that have the potential
for use in nanocells as reduced toxicity alternatives to traditional chemotherapy agents.
Thesis Supervisor: Ram Sasisekharan, Ph.D., Director, Harvard-MIT Division of Health
Sciences and Technology / Edward Hood Taplin Professor of Health Sciences & Technology and
Biological Engineering
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1.1. Background
1.1.1. Motivation
New therapies for cancer that initially show promise in animal models and early clinical
trials are often a disappointment over the long term when drug resistance develops and the final
outcome is not a success. Until recently, drug resistance has been defined almost exclusively in
terms of cellular mechanisms through which tumor cells are resistant to treatment. Recent
findings have shown that the tumor microenvironment may also contribute to drug resistance
through non-cellular mechanisms'. One such mechanism results from the formation of isolated
regions of hypoxia due to the heterogeneous vascularization of solid tumor. Not only are
hypoxic cells in these regions less accessible to blood-borne chemotherapeutic agents, these
hypoxic cells also release factors responsible for the promotion of tumor growth, angiogenesis,
2,
and metastasis' 3. Of particular concern for combination chemotherapy is the potential for
increased microenvironment mediated drug resistance after treatment with anti-angiogenic
agents.
The term angiogenesis describes the formation of new capillaries from existing
vasculature (for review see4). While the adult vasculature is primarily quiescent, angiogenesis
occurs physiologically during embryonic development, wound healing, and the menstrual cycle.
Angiogenesis is also implicated in certain pathological conditions including cancer. As a tumor
undergoes rapid growth, existing vasculature is co-opted to ensure that cells maintain an
adequate nutrient supply and are able to efficiently remove waste5 '6 . Vascular cooption is
confined to the tumor periphery and gradual tumor expansion causes a progressive central
hypoxia. In order for these hypoxic cells to survive they must switch to an angiogenic
phenotype7'. Some tumor clones remain dormant for many months and are thus confined within
several millimeters in diameter until they activate an angiogenic pathway9 . Hypoxia, through
hypoxia inducible factor-a, induces the expression of pro-angiogenic factors and may result in an
angiogenic phenotype if proangiogenic factors are in excess of antiangiogenic factors0 . The
balance between proangiogenic and antiangiogenic conditions is affected by a variety of factors
11including metabolic and mechanical stresses, hypoxia, and genetic mutations
Once initiated, tumor angiogenesis is characterized by a regulated series of sequential
steps (for review see"). Angiogenic factors produced by tumor cells bind to endothelial cell
receptors and initiate angiogenesis. Matrix metalloproteinases (MMPs), released by activated
endothelial cells, degrade the basement membrane and extracellular matrix (ECM) surrounding
already existing capillaries near the tumor site. The break-up of ECM releases additional pro-
angiogenic factors further enabling the switch to an angiogenic phenotype2. Pro-angiogenic
stimuli cause endothelial cell junctions to become altered with newly formed cell projections
growing towards the source of the stimulus. Endothelial cells then migrate into the tumor ECM
and proliferate. There, newly formed endothelial cells organize into hollow tubes in a process
called canalization. The fusing of these newly formed vascular tubes with the creation of new
basement membrane enables blood flow within the tumor.
The vascular density of tumors is highly heterogeneous, and tumor blood vessels exhibit
many abnormalities when compared to normal vessels including a high percentage of
proliferating endothelial cells, an increased tortuosity, and aberrant basement membrane
formation . As a result, tumor blood vessels exhibit marked extravasation or vessel wall
hyperpermeability. Molecular transport across tumor vessels may occurr via a number of
pathways including interendothelial junctions and transendothelial channels, vesicular vacuole
organelles, and fenestrations 5 . The pore cutoff size of the tumor vasculature varies depending
15, 16
upon tumor model, however it is most commonly reported to range between 400 and 800nml
The first convincing evidence that tumor growth may be angiogenesis dependent came in
1968 with an experiment demonstrating that implanted tumor tissue in non-vascularized rabbit
cornea did not grow until newly formed vessels from the limbus reached the implant". Since
then, a large body of work has gone into uncovering the factors responsible for promoting tumor
angiogenesis as potential targets for new therapy. Such factors currently include vascular
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived
endothelial growth factor (PDGF), fibronectin, scatter factor (SF), and others (for review see 18
Currently explored anti-angiogenic agents are of at least three classes: agents that are directly
cytotoxic or static against endothelial cells, agents that inhibit growth factor release, and agents
that block growth factor signaling (for review see 19)
Several angiogenic inhibitors are currently under study in Phase I, II, and III clinical trials
(see http://www.cancer.gov/clinicaltrials for current trials). Contrary to a promising body of
successful work using anti-angiogenics in animal tumor models, the best outcomes from these
clinical studies have been, with few exceptions, stabilization of tumor growth over a defined
period 20. An explanation for these relatively disappointing findings has been offered on several
rationales 20 . Most animal studies on which the success of anti-angiogenics are based are
performed with ectopically growing subcutaneously implanted tumors. Due to the relative
sparseness of vasculature within the subcutis, tumors in these studies are then expected to be
more dependent on new vessel formation than tumors that grow orthotopically2 1 . Also, tumor
cells used in animal studies are highly selected compared to the heterogeneous mixture of cells
found in patients. Tumor cells expressing specific genetic markers have demonstrated marked
susceptibility or resistance to anti-angiogenic treatments . Further difficulty in analyzing the
effect of anti-angiogenics comes from finding clinical parameters for measuring their success.
With current cytotoxic therapies, tumor reduction is the major parameter for measuring treatment
success. With anti-angiogenics, however, the lack of tumor regression may not always indicate a
19failure, as the mechanism of action of anti-angiogenics is often cytostatic in nature
While there is compelling experimental evidence that at least certain types of tumors are
angiogenesis dependent, recent clinical trials have demonstrated that purely anti-angiogenic
treatments are not as effective for achieving tumor regression as was originally hoped. The
growing consensus is towards combination therapy 7, 19,20, using anti-angiogenics as well as
traditional chemotherapy for a synergistic effect. This, however, has been more difficult than
was originally anticipated. While combination therapy has been shown in many cases to be
beneficial 24, 25, recent evidence has demonstrated that interactions between anti-angiogenic and
cytotoxic agents may in fact be antagonistic in certain tumor models. Anti-angiogenics, by
cutting off the tumor blood supply, may in turn induce new regions of tumor hypoxia3 26 . Tumor
hypoxia not only contributes to the induction of angiogenesis through the release of hypoxia
inducible factor-a, but it also has been correlated with an increase in tumor invasion and
metastasis3 . Of particular concern is the effect of hypoxia on the efficacy of traditional
chemotherapeutic agents. While it can be expected that reduced blood flow within the tumor
will reduce the access of an intravenously administered drug, hypoxia has also been shown to
contribute directly to cytotoxic drug resistance over a range of tumor models. While this
resistance is likely due in part to reduced cell proliferation within hypoxia regions of tumor27,
upregulation of hypoxia inducible factor-a has also been correlated with the upregulation of the
anti-apoptotic protein Bcl-2 and the multi-drug resistance product P-glycoprotein28 ,29
Nanoscience has been described as one of the most important research and development
frontiers in modem science30. Nanoscale particles have found use in medicine as vehicles for
DNA transfection, enzyme encapsulation, biosensors, and drug delivery 30. The use of these
particles in drug delivery has offered considerable promise for the enhanced delivery of
chemotherapeutic agents. Encapsulation within or binding to small colloidal particles enables
drugs in many cases to circulate longer, accumulate preferentially within tumor tissue, have
reduced systemic toxicity, undergo controlled release, and even bypass certain cellular
mechanisms of drug resistance (for review see 3 1). Our primary goal in this work is to combine
leading nanoscience technology with new understandings of tumor pathophysiology,
angiogenesis, and micro-environment mediated drug resistance to develop novel strategies for
treatment that improve drug efficacy, reduce toxicity, and limit certain types of drug resistance to
increase chances for therapeutic success over the long-term.
1.2. Introduction: New Paradigm of Spatio-Temporal Drug Delivery
In light of the motivation described above, the specific objectives of this thesis are as
follows:
1. To exploit the pathophysiology of solid tumors and enhance combination chemotherapy
regimens by engineering novel nanoscale delivery vehicles termed 'nanocells.' (Chapter
2.1 and 2.2)
a. To assess the therapeutic benefit of this delivery platform.
b. To demonstrate that any increased therapeutic benefit is due to both the controlled
spatial and temporal release of the encapsulated agents, as indicated by the tumor
pathophysiology.
2. To develop new tools and strategies for optimizing nanocell formulations. (Chapter 2.3
and 2.4)
a. To develop a new computational model for drug release from nanoscale delivery
systems. A better understanding of nanoscale drug release will facilitate the
future optimization of nanocell spatio-temporal release profiles.
b. To generate and characterize a new set of carbohydrate-based anti-tumor agents
with low systemic toxicity. Anti-tumor carbohydrates may be used in nanocells
as reduced toxicity alternatives to traditional chemotherapeutic agents.
The thesis is written such that Chapter 1 presents an outline of the motivation for the
entire body of work as well as an introduction to how each of the thesis objectives will be met.
Chapter 2.1 presents the nanocell which is a nanoscale drug delivery vehicle for the controlled
spatio-temporal delivery of multiple anti-tumor agents. The nanocell comprises a nuclear
polymeric nanoparticle encapsulated within a lipid envelope, and the entire vehicle is
preferentially taken up by the tumor. The nanocell enables a temporal release of two drugs: the
outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner
nanoparticle, which is trapped inside the tumor, then releases a chemotherapy agent. This focal
release within a tumor results in improved therapeutic index with reduced toxicity. The
technology can be extended to additional agents, so as to target multiple signaling pathways or
distinct tumor compartments, enabling the model of an 'integrative' approach in cancer therapy.
Chapter 2.2 presents a modified nanoscale delivery vehicle for imaging angiogenesis. As
tumors undergo rapid growth, they must generate their own vascular network in order to provide
the nutrients necessary for continued expansion and spread. In vivo imaging of tumor
vascularization is now of paramount importance, as this is both a sign of increasing tumor
malignancy and a potential target for new therapies. We demonstrate here a method for imaging
and specifically identifying tumor-specific vasculature using quantum dots encapsulated within
nanoscale lipid membranes, combining the fluorescent properties of quantum dots with the
bioavailability and tumor-specific interstitial uptake of the lipid vehicle.
Chapter 2.3 presents a new computational model for drug release from nanoscale delivery
vehicles. The use of polymeric nanoparticles as drug delivery devices is becoming increasingly
prevalent in a variety of therapeutic applications. Despite their widespread clinical use, the
factors influencing the release profiles of nanoparticle-encapsulated drugs are still not
quantitatively understood. We present here a new, semi-empirical model of drug release from
polymeric nanoparticles using a formulation of dexamethasone encapsulated within poly(lactic-
co-glycolic acid) PLGA to set model parameters. We introduce a three-dimensional voxel-based
framework for Monte Carlo simulations that enables direct investigation of the entire spherical
nanoparticle during particle degradation and drug release. Due to implementation of this model
at the nanoscale, we utilize assumptions that simplify the model while still allowing multi-phase
drug release to be simulated with good correlation to experimental results.
Chapter 2.4 presents the generation and characterization of new anti-tumor carbohydrate
based agents. We demonstrate here an integrative approach for the standardization and structure-
function analysis of a new class of anti-tumor modified pectins classified here as activated citrus
pectin (ACP) generated from native citrus pectin (NCP) which is isolated directly from lemon.
We incorporate complementary analytical techniques to link ACP structure with binding to
tumor galectin targets. We further provide evidence for a mechanism of action by elucidating
key constituents of an ACP-induced anti-tumor intracellular signaling cascade. A better
understanding of ACP anti-tumor activity as it relates to its structural modification will allow the
synthesis of more effective and more reliable anti-tumor pectin agents. The polymeric nature of
this carbohydrate further facilities its incorporation into future nanocell formulations.
Chapter 3 provides integrated conclusions for the body of work, and introduces
applications that are being investigated as future directions. The remainder of Chapter 1 will
introduce each of the topics covered throughout the thesis in additional detail.
1.2.1. The Nanocell
Current combination therapy regimens commonly consist of frequent dosing with anti-
angiogenics interspersed with single large doses of anti-cancer agents24'25'32, however we
propose that a delivery system enabling the focal build-up of a cytotoxic agent within
vascularized regions of the tumor immediately prior to anti-angiogenic therapy would not only
allow for greater bioavailability of the drug within the tumor but also target the cells most at risk
for hypoxia, thus inhibiting the formation of new regions of hypoxia after therapy. Collapse of
the tumor vasculature immediately after the focal loading of the cytotoxic agent would provide
the added benefit of trapping the drug within the tumor, reducing systemic toxicity while
promoting drug action.
Recently, the design of multichamber nanoparticle devices has been of benefit for
improving the utility of nanotechnology in biomedical applications. The encapsulation of
fluorescent semiconductor nanocrystals (quantum dots) within block-copolymer micelles has
enabled enhanced biocompatibility for both in vitro and in vivo imaging3. Micellar
nanocontainers consisting of a core containing an active therapeutic agent surrounded by a
block-copolymer micelle has assisted in water dispersability of the agent and efficient delivery to
specific cytoplasmic organelles3 4 . Drug-loaded polymeric chitosan vesicles encapsulated within
lipid have been demonstrated to enable controlled release of a single agent altered by the
presence of the outer lipid chamber 35. The advantages and disadvantages of current combination
therapy discussed above have established a potential benefit for single vehicles able to deliver
multiple drugs having different modes of action with controlled and distinct release properties.
The use of multi-chambered nanodelivery vehicles has logical extensions to this application.
We demonstrate in this work a novel nanodelivery system for the spatio-temporal
recruitment of anti-angiogenics and traditional cytotoxic agents at the site of tumor for a more
optimal anti-tumor effect than standard co-administration of the two therapies. This delivery
system consists of a small (<1 00nm) polymeric nanoparticle surrounded by a larger (~200nm)
spherical lipid bilayer shell. Both the nanoparticle and the surrounding lipid shell are able to
encapsulate separate chemotherapeutic agents with different release characteristics. In this case,
the cytotoxic drug doxorubicin is covalently encapsulated within the nanoparticle, while the anti-
angiogenic agent combretastatin A4 is preferentially partitioned within the lipid bilayer. These
drug-loaded 'nanocells' are passively taken up by the tumor's leaky vasculature through
extravasation, though they may also be targeted to tumor by means of ligand or antibody
binding. We demonstrate here that this spatio-temporal targeting of anti-angiogenics and
cytotoxic agents enables a substantially greater anti-tumor effect than traditional co-
administration of the two agents, as well as reduced systemic toxicity and tumor metastasis.
1.2.2. New Mechanistic Understandings of Nanoscale Drug Delivery
Optimization of the nanocell release profiles for different drug combinations and
different tumor models will benefit from new understandings of the mechanisms of drug release
from nanoscale delivery vehicles. Numerous mathematical and computational models have been
reported in the literature to describe drug release and particle breakdown for polymer-based
delivery vehicles, though none have yet been able to quantitatively account for all factors
22,36143
relevant to drug release 22 . Primarily governing drug release from bulk eroding polymers are
the mass transport processes of drug diffusion and dissolution and the chemical processes of
polymer degradation and erosion. These phenomena are typically modeled using one of two
modeling approaches classified as diffusion-and-reaction and cellular automata models.
Diffusion and reaction models normally use a variant of Fick's second law of diffusion to model
the events of diffusion and dissolution with the subsequent influence of polymer erosion. An
early model developed by Harland et al was one of the first to take into account these processes
for drug release from spherical microparticles. 4 ' 45 Later studies included the influence of
polymer degradation on diffusion through erosion-dependent diffusivities 46' 47, though it has been
noted that this influence is not mechanistically modeled48 . Cellular automata models are
designed to simulate drug release by considering the process of matrix erosion as a random
event. Since these models typically evaluate polymer degradation and erosion as the rate
limiting steps, they are normally used for modeling drug release from surface-eroding polymers
where the influence of mass transport phenomena on drug release is reduced.
It is increasingly clear from existing models that the number of factors that influence the
release of an agent from a polymer matrix is too unwieldy for a single model to incorporate.
Such factors include water and drug diffusion, drug dissolution, polymer molecular weight,
particle size and geometry, polymer degradation, micro-environment pH changes, autocatalysis,
44 48 49
polymer swelling, and more 4''4. Incorporation of all these factors is further complicated by a
still incomplete understanding of the extent to which they influence the kinetics of drug release.
Notably, very little has been reported regarding the modeling of drug release from polymeric
nanoparticles, though these are becoming increasingly prominent in cancer therapeutics.
We present here a new, semi-empirical model of drug release from polymeric
nanoparticles using a formulation of dexamethasone encapsulated within poly(lactic-co-glycolic
acid) PLGA to set model parameters. We introduce a three-dimensional voxel-based framework
for Monte Carlo simulations that enables direct investigation of the entire spherical nanoparticle
during particle degradation and drug release. Due to implementation of this model at the
nanoscale, we utilize assumptions that simplify the model while still allowing multi-phase drug
release to be simulated with good correlation to experimental results.
1.2.3. Development of Reduced-toxicity Antitumor Agents
It is our hope that the development of novel therapeutic compounds with reduced toxicity
and utility both as structural and bioactive components will lead to more streamlined and
efficient nanocells with rapid clinical application. One class of therapeutic agents that holds
promise for this role is the carbohydrate pectin.
Pectin is a major component of all primary cell walls and consists of a complex
carbohydrate network composed predominantly of galacturonic acid rich polysaccharides. In
order to characterize this network, pectin has been divided into three major structural pectic-
polysaccharides: homogalacturonan (HGA), rhamnogalacturonan-I (RG-I), and
rhamnogalacturonan-II (RG-II). 0 HGA is a linear, unbranched polysaccharide consisting of
(1 -+4)-a-linked-D-galacturonic acids containing 100-200 GalA residues. Methylesterification at
the C-6 carboxyl occurs in 70-80% of the GalA residues. RG-I consists of as many as 100
repeats of the disaccharide (1 -+2)-a-L-rhamnose-(1 -*4)-a-D-galacturonic acid. Rhamnose
residues in RG-I may be substituted at C-4 with predominantly neutral residue side chains which
can vary in size from a single glycosyl residue to 50 or more, resulting in highly branched
regions of pectin. In contrast to the first two pectin domains, RG-II appears to be a highly
conserved and stable pectin domain. RG-II is not structurally related to RG-I, but instead is a
branched pectic domain containing an HGA backbone. The RG-II backbone is substituted by 4
heteropolymeric side chains of consistent lengths containing eleven different sugars including
apiose, aceric acid and 2-keto-3-deoxy-D-manno-octulosonic acid.
This complex pectin matrix may be fragmented via temperature, pH, or enzymatic
modification into shorter, soluble oligosaccharide chains. One method of fractionating pectin
has led to a subpopulation of pectin fragments with anti-tumor activity. These shorter pectin
chains dissolve more readily in water and it is believed that they contain polysaccharides having
affinity for cell-surface galectin-35 1 . Galectins are a family of animal lectins defined by their
ability to recognize p-galactose and by conserved amino acid residues within the carbohydrate
recognition domains. Currently 15 mammalian galectins have been identified, with several
implicated in regulation of tumor apoptosis, inflammation, and immune escape . Anti-tumor
pectins have demonstrated therapeutic benefit for inhibiting tumor growth, adhesion, metastasis,
and angiogenesis in several tumor models over the past decade including melanoma5 1 , 53, breast
cancer 4, and colon cancer 4, and one pilot phase II human clinical trial for prostate cancer
The cheap, ready availability of pectin in combination with a virtual total lack of negative side
effects has made understanding the mechanism of action of these intriguing new anticancer
molecules of critical importance.
The proposed therapeutic mechanism is currently based upon evidence for the binding of
pectin to galectin-3 54 and similarities between the activity of pectin and the activity of galectin-3
for inhibiting tumor function 1 . No direct mechanism has yet been elucidated, and this is
probably due to multiple considerations. First, the temperature and pH modifications used to
generate anti-tumor pectin are likely dependent upon the pectin starting source. Pectins obtained
from major research laboratory vendors have considerable batch-to-batch variability in methods
of isolation, and so can be expected to have substantial variations in starting structure. Despite
this limitation, currently published anti-tumor pectin studies all use pre-processed pectins51'53-57.
The variability of pectin structures between studies also contributes to the challenge of
identifying structure-function relationships relating pectin structure and anti-tumor activity.
Second, while galectin-3 appears to play a probable role in pectin mediated anti-tumor activity,
the mechanism of action may not be entirely due to this galectin. Additional galectins, including
galectin- 158,59, have established roles in regulating tumor apoptosis, angiogenesis, and immune
escape, and also have affinity for residues present within the complex polysaccharide
60
environment of the pectin matrix
We demonstrate here an integrative approach for the standardization and structure-
function analysis of a new class of anti-tumor modified pectins classified here as activated citrus
pectin (ACP) obtained by a new methodology from a consistent source of native citrus pectin
(NCP) isolated directly from lemon. We incorporate complementary analytical techniques to
link ACP structure with binding to tumor galectin targets. We further establish a potential
mechanism of action by elucidating key constituents of an ACP-induced anti-tumor intracellular
signaling cascade. A better understanding of ACP anti-tumor activity as it relates to its structural
modification will allow the synthesis of more effective and more reliable anti-tumor pectin
agents. Further, pectin already has established use as a purely structural component in multiple
modes of drug delivery formulations, 61-63 and ACP should incorporate well into future nanocell
formulations.
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2. Novel Nanoscale Delivery Systems for Combination Chemotherapy
This chapter (2.1) presents the nanocell: a multi-compartmental nanoscale drug delivery
vehicle for the controlled spatio-temporal delivery of combination chemotherapy. The nanocell
comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is
preferentially taken up by the tumor. The nanocell enables a temporal release of two drugs: the
outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner
nanoparticle, which is trapped inside the tumor, then releases a chemotherapy agent. This focal
release within a tumor results in improved therapeutic index with reduced toxicity. The
technology can be extended to additional agents, so as to target multiple signaling pathways or
distinct tumor compartments, enabling the model of an 'integrative' approach in cancer therapy.
This chapter (2.2) also presents a modified nanoscale delivery vehicle for imaging
angiogenesis. As tumors undergo rapid growth, they must generate their own vascular network
in order to provide the nutrients necessary for continued expansion and spread. In vivo imaging
of tumor vascularization is now of paramount importance, as this is both a sign of increasing
tumor malignancy and a potential target for new therapies. We demonstrate here a method for
imaging and specifically identifying tumor-specific vasculature using quantum dots encapsulated
within nanoscale lipid membranes, combining the fluorescent properties of quantum dots with
the bioavailability and tumor-specific interstitial uptake of the lipid vehicle.
This chapter (2.3) also presents a new computational model for drug release from
nanoscale delivery vehicles. The use of polymeric nanoparticles as drug delivery devices is
becoming increasingly prevalent in a variety of therapeutic applications. Despite their
widespread clinical use, the factors influencing the release profiles of nanoparticle-encapsulated
drugs are still not quantitatively understood. We present here a new, semi-empirical model of
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drug release from polymeric nanoparticles using a formulation of dexamethasone encapsulated
within poly(lactic-co-glycolic acid) PLGA to set model parameters. We introduce a three-
dimensional voxel-based framework for Monte Carlo simulations that enables direct
investigation of the entire spherical nanoparticle during particle degradation and drug release.
Due to implementation of this model at the nanoscale, we utilize assumptions that simplify the
model while still allowing multi-phase drug release to be simulated with good correlation to
experimental results.
This chapter (2.4) also presents the generation and characterization of new carbohydrate-
based anti-tumor carbohydrates. We demonstrate here an integrative approach for the
standardization and structure-function analysis of a new class of anti-tumor modified pectins
classified here as activated citrus pectin (ACP) obtained by a new methodology from a consistent
source of native citrus pectin (NCP) isolated directly from lemon. We incorporate
complementary analytical techniques to link ACP structure with binding to tumor galectin
targets. We further provide evidence for a mechanism of action by elucidating key constituents
of an ACP-induced anti-tumor intracellular signaling cascade. A better understanding of ACP
anti-tumor activity as it relates to its structural modification will allow the synthesis of more
effective and more reliable anti-tumor pectin agents. The polymeric nature of this carbohydrate
further facilities its incorporation into future nanocell formulations.
2.1. Spatio-temporal Targeting of Tumor Cells and Neovasculature: The Nanocell
2.1.1. Introduction
The material found in Chapter 2.1 has previously been published: Sengupta and Eavarone
et al, Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system.
Nature 436, 568-72 (2005) and has been reprinted with permission. In the continuing search for
effective treatments for cancer, the emerging model is the combination of traditional
chemotherapy with anti-angiogenesis agentsI that inhibit blood vessel growth. However, the
implementation of this strategy has faced two major obstacles. First, the long-term shutdown of
tumor blood vessels by the anti-angiogenesis agent can prevent the tumor from receiving a
therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the
intra-tumoral accumulation of hypoxia-inducible factor-i a (HIF 1 -a); overexpression of HIF 1 -a
is correlated with increased tumor invasiveness and resistance to chemotherapy.2,3,4,5 Here we
report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes
these barriers unique to solid tumors. The nanocell comprises a nuclear nanoparticle within an
extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumor. The nanocell
enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis
agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumor,
then releases a chemotherapy agent. This focal release within a tumor results in improved
therapeutic index with reduced toxicity. The technology can be extended to additional agents, so
as to target multiple signaling pathways or distinct tumor compartments, enabling the model of
an 'integrative' approach in cancer therapy.
Although the inhibition of angiogenesis is an elegant concept in cancer therapy', there are
concerns about its implementation. Anti-angiogenesis therapy-induced tumoral hypoxia
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upregulates genes2 that can significantly reduce the pro-apoptotic effect of chemotherapy 3
leading to 'reactive resistance'4' 5 . Furthermore, the activation of the hypoxic response can
enhance the metastatic and invasive potential of tumor cells 6'7 , although this has not been
resolved clinically. We reasoned that the optimal strategy to overcome these limitations is to
sequentially expose the tumor to cytotoxic agents after a vascular shutdown induced by anti-
angiogenesis therapy. However, two issues complicate this approach. First, the suppression of
tumor growth requires long-term administration of angiogenesis inhibitors, whereas
chemotherapy is usually given in short treatment cycles9 . Second, the chronic administration of
an anti-angiogenesis agent impairs blood flow inside the tumor microenvironment, precluding
the intra-tumoral build-up of a therapeutically effective concentration of the chemotherapeutic
agent.
2.1.2. Materials and Methods
Synthesis and characterization of nanocells
Activated PLGA was dissolved in dimethylformamide and reacted with doxorubicin and
triethylamine at room temperature (20 'C) under a nitrogen atmosphere (stoichiometric molar
ratio of activated PLGA:doxorubicin:triethylamine, 1:1:4)13. Nanoparticles were formulated
from the PLGA copolymer-doxorubicin conjugates by using an emulsion-solvent evaporation
technique. For scanning electron microscopy, dehydrated nanoparticles were coated with gold
on a carbon grid. They were analysed using a Jeol electron microscope (magnification times
3,700). Nanoparticle size fractions were recovered by ultracentrifugation at 10,000 g, 25,000 g
and 50,000 g, which also removed free doxorubicin from the PLGA-doxorubicin conjugates.
The smallest fraction was extruded through a membrane (pore size 100 nm) to obtain
nanoparticles for encapsulation within nanocells. Phosphatidylcholine:cholesterol:PEG-DSPE
(2:1:0.2 molar ratio) lipid membranes were prepared by dissolving the lipids in chloroform in a
round-bottomed flask. Combretastatin A4 was added at a 0.9:1 drug:lipid molar ratio. To
fabricate the nanocells, doxorubicin-conjugated nanoparticles were added to the aqueous lipid
resuspension buffer, which was extruded through a membrane (pore size 200 nm). Sizing was
performed by dynamic light scattering and transmission electron microscopy. For additional
information see supplementary methods.
Cell culture studies
B 16/F 10 cells were plated at a concentration of 5 times 104 cells per well and left to grow
for 24 h in 5% fetal calf serum. The cells were exposed to increasing concentrations of free or
nanoparticle-conjugated doxorubicin and incubated for 48 h, after which the cells were counted
with the Trypan blue exclusion method. EC50 was calculated by curve-fitting. For additional
information see supplementary methods.
Release kinetics characterization
Drug-loaded nanocells were suspended in 1 ml of PBS buffer or hypoxic-cell lysate and
sealed in a dialysis bag (molecular mass cut-off 10 kDa). The dialysis bag was incubated in 20
ml of PBS buffer at 37 'C with gentle shaking. Aliquots were extracted from the incubation
medium at predetermined intervals, and released drug was quantified by reverse-phase HPLC
with a C18 column, using a linear gradient of acetonitrile and water eluents. For additional
information see supplementary methods.
In vitro tumor-endothelium co-culture studies
The co-culture of GFP-positive B 16/F10 melanoma with human umbilical vein
endothelial cells on a three-dimensional Matrigel matrix was exposed to different treatments.
The cells were fixed with 4% paraformaldehyde, incubated with propidium iodide and analysed
with a confocal microscope. Quantification was performed with a planimetric point-count
method using a 224-intersection point square reticulum. Data were expressed as the ratio of each
component to the total area covered by cells. For additional information see supplementary
methods.
In vivo tumor studies
GFP-positive BL6/F10 melanoma cells (3 times 105) or Lewis lung carcinoma cells (2.5
times 105) were implanted in male C57/BL6 mice. Treatment was started when the tumors
reached 50 mm3 in volume. Each formulation was prepared, quantified and diluted so that 100
microl (intravenous) was equivalent to 50 mg kg-1 combretastatin and 500 microg kg-1
doxorubicin. The animals were killed at defined time points, and the tumors were excised for
histopathology. Simultaneously, 1 ml of blood was drawn through cardiac puncture and
analysed for a toxicity profile of the treatment regimens. For additional information see
supplementary methods.
Tissue distribution studies
Nanocells were fabricated with fluorescein dye and injected into tumor-bearing mice.
The animals were killed at 5, 10 and 24 h after injection. Serum, tumor, liver, lungs and spleen
were collected during necropsy, and fluorescein was extracted from these tissues with methanol,
detected with a fluorescence plate reader, and normalized to the tissue weight. In another study,
nanocells were fabricated with Quantum Dots in the core, and injected intravenously into tumor-
bearing mice. The animals were killed at different time points, and the highly vascular organs
were extracted during necropsy. The tissue sections (30 microm thick) were immunostained to
delineate the blood vessels. Confocal images were captured at 512 pixels times 512 pixels
resolution, with excitation using a 488-nm laser line and emissions at the fluorescein
isothiocyanate (FITC)/rhodamine wavelengths. Depth-coding was performed with LSM5 10
software. For additional information see supplementary methods.
Immunohistology
For analysis of tumor vasculature, permeabilized cryosections of the tumors were
immunoprobed for vWF, an endothelial cell marker. For study of apoptosis, TUNEL staining
was performed with Texas red-labeled nucleotide in accordance with the manufacturer's
instructions (Roche). The same sections were also stained simultaneously for HIF 1-a, using
appropriate primary and FITC-labelled secondary antibodies. Images were captured with a Leica
LSM5 10 confocal microscope at a 512 pixels times 512 pixels resolution. For quantifying
metastatic nodes, the liver and lungs were harvested from the animals during necropsy, fixed in
paraformaldehyde and embedded in paraffin. Thin sections were stained with
haematoxylin/eosin and imaged with a Zeiss LSM5 10 confocal microscope with
FITC/rhodamine filters. Metastatic nodes were quantified by counting the number of yellow foci
in each section. For additional information see supplementary methods.
Western blotting
Tissue samples were lysed in sample buffer and resolved on a 4-12% gradient SDS-
polyacrylamide-gel electrophoresis gel. The proteins were transferred to a nitrocellulose
membrane, blocked, and probed with the appropriate primary antibodies and secondary
horseradish peroxidase-labelled antibodies. Proteins were detected by chemiluminescence and
quantified with a Kodak 2000 gel-imaging system. For additional information see
supplementary methods.
2.1.3. Results and Discussion
To address this challenge we designed a novel delivery system, termed a nanocell,
comprising a nanoscale pegylated-phospholipid block-copolymer envelope coating a nuclear
nanoparticle. A chemotherapeutic agent is conjugated to the nanoparticle and an anti-
angiogenesis agent is trapped within the lipid envelope. We proposed that the disruption of this
envelope inside a tumor would result in a rapid deployment of the anti-angiogenesis agent,
leading to vascular collapse and the intra-tumoral trapping of the nanoparticles (Fig. 1). The
subsequent slow release of the cytotoxic agent from the nanoparticle should then kill the tumor
cells.
As a proof of concept, we selected doxorubicin and combretastatin-A4 as the cytotoxic
agent and the anti-angiogenesis drug, respectively. Doxorubicin induces apoptosis by
intercalating with the DNA, causing scission'0 . Combretastatin causes a rapid vascular shutdown
inside a tumor by disrupting the cytoskeletal structures'. The nanoparticles were fabricated
from the biodegradable and nonbioactive copolymer poly-(lactic-co-glycolic) acid (PLGA).
Doxorubicin was conjugated to PLGA (Fig. 2a) to achieve a slow release profile, distinct from
the characteristic 'burst' release associated with nanoparticles. In vitro cell culture studies
revealed a shift in the concentration-effect curve of the doxorubicin-PLGA conjugate, for which
the concentration giving half-maximal response (EC50) was about 10.59 microg, compared with
free doxorubicin (EC50 approximately 5.93 microg; Fig. 3c). This shift in the concentration-
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Figure 1. Diagram of nanocell therapy. Current combination therapy regimens commonly
consist of frequent dosing with anti-angiogenics interspersed with single large doses of anti-
cancer agents, however we propose that a delivery system enabling the focal build-up of a
cytotoxic agent within vascularized regions of the tumor immediately prior to anti-angiogenic
therapy would not only allow for greater bioavailability of the drug within the tumor but also
target the cells most at risk for hypoxia, thus inhibiting the formation of new regions of hypoxia
after therapy. Collapse of the tumor vasculature immediately after the focal loading of the
cytotoxic agent would provide the added benefit of trapping the drug within the tumor, reducing
systemic toxicity while promoting drug action. Gray shading: hypoxic tumor cells; brown
shading: necrotic tumor cells.
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Figure 2. Synthesis and characterization of a combretastatin-doxorubicin nanocell. a,
Diagram of conjugation reactions between doxorubicin and PLGA 5050.DMF,
dimethylformamide; pNC, p-nitrophenyl-chloroformate; TEA, triethylamine. b, Scanning
electron micrograph of heterogeneous nanoparticles. c, Combretastatin is encapsulated in the
lipid envelope. d, Transmission electron micrograph of the cross-section of three nanocells
shows the dark nuclear nanoparticle within the phospholipid block-copolymer envelope. e,
Dynamic light scattering shows that nanoparticles of defined sizes were used for encapsulation
within the envelope. f, Physicochemical release kinetics shows the temporal release of
combretastatin (triangles, scale in 102 microg) and doxorubicin (squares, scale in microg).
Results are means plus/minus s.e.m. (n = 4). Asterisk, P < 0.002; hash, P < 0.001.
effect curve indicates that the doxorubicin-PLGA oligomers are inactive and have to degrade
further into bioactive doxorubicin-PLGA fragments and free drug, which is consistent with
earlier reports13 . Although there was heterogeneity in the sizes of nanoparticles synthesized (Fig.
2b), we isolated a homogeneous population of nanoparticles between 80-120 nm (Fig. 2e).
To synthesize the nanocell, these nanoparticles were nucleated inside a nanoscale
phospholipid block-copolymer envelope composed of 2,000-Da poly-(ethylene glycol)
distearoylphosphatidylethanolamine (PEG-DSPE), phosphatidylcholine and cholesterol, in an
optimal ratio with combretastatin. The selection of combretastatin, a lipophilic cis-stilbene (Fig.
2c), allowed optimal loading by partitioning into the lipid bilayer. Transmission electron
microscopy showed the ultrastructure as being similar to a biological cell-a nuclear core
surrounded by a lighter lipid membrane-hence the metaphor 'nanocell' (Fig. 2d). The size of
the nanocells ranged between 180 and 200 nm in diameter (Fig. 2e).
To evaluate the nanocell physicochemically, we quantified the release kinetics for each
drug. We observed a rapid release of combretastatin, reaching significant levels within 12 h. In
contrast, the doxorubicin-PLGA oligomer was found to degrade into smaller doxorubicin-PLGA
fragments and free doxorubicin significantly more slowly (Fig. 2f), extending over 15 days. This
slow release underlines the shift in the concentration-effect curves, the EC50 being calculated at
a time before the complete breakdown of the drug-polymer conjugate.
To correlate the temporal-release kinetics with the pathophysiology, we harnessed a
tumor-endothelium co-culture bioassay14 . The co-cultures were exposed to different treatments
for defined periods, after which they were evaluated by dual-fluorescence confocal microscopy.
As shown in Fig. 3, prolonged (30 h), but not short (12 h), incubation of the co-culture with
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Figure 3: Bioassay of the nanocell with a GFP-positive melanoma-endothelial cell three-
dimensional co-culture system. a, Micrographs showing the effect of treatments on melanoma
(yellow) or endothelium (red). b, Stereological quantification of the result. Treatment with
nanocells (NC) results in temporal ablation of vasculature followed by destruction of the tumor
cells. Liposomal combretastatin (250 microg ml') (L[C]) and doxorubicin-conjugated
nanoparticles (ND) (20 microg ml' doxorubicin) results in selective loss of vasculature and
tumor respectively. Results are means plusminus s.e.m. from three independent experiments. V,
vehicle. Three asterisks, P < 0.001 (analysis of variance with Bonferroni's post-hoc test). c,
Concentration-effect curve of free doxorubicin (triangles) and PLGA-conjugated doxorubicin
(squares) on B16/F10 cells. Results are means plus/minus s.e.m. for two independent
experiments.
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doxorubicin-conjugated nanoparticles, alone, resulted in a complete ablation of the tumor cells
without affecting the endothelial cells. This was consistent with the results obtained with free
doxorubicin . In contrast, incubation with combretastatin-encapsulated liposomes resulted in a
rapid collapse of the vascular network without affecting the tumor cells. In the nanocell-treated
groups, collapse of the vasculature was evident as early as 12 h, at which time point the tumor
cells remained unaffected. A complete ablation of the co-culture was achieved by 30 h, which is
consistent with the kinetics profile of the drug release rate. Although this release profile may not
mimic the in vivo state, the close similarity of ex vitro release profiles in hypoxic-tumor cell
lysate and PBS, together with the bioassay results, emphasizes that a similar release pattern over
time would be functional in the acidic microenvironment of the tumor.
To validate the therapeutic efficacy of this treatment, we randomly sorted mice bearing
established (green fluorescent protein (GFP)-positive) B 16/F10 melanomas or Lewis lung
carcinoma into six groups and treated each group with one of the following: PBS (control);
nanocells containing doxorubicin nanoparticles but lacking combretastatin (NC[D]);
combretastatin-encapsulated liposomes (L[C]); co-administration of NC[D] + L[C]; nanocells
containing both doxorubicin and combretastatin (NC); and a simple liposomal system
encapsulating both doxorubicin and combretastatin (L[CD]). A separate melanoma-bearing
group received half the dose of NC. The mice injected with PBS formed large tumors by day 17
(the day after the last injection), and consequently were killed. The animals in the other groups
were also killed at the same time point to evaluate the effect of the treatments on tumor
pathology. In a separate experiment, another group of animals was given seven cycles of
treatment with NC to evaluate the effect over a longer period.
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Figure 4: Nanocell therapy inhibits B16/F1O melanoma and Lewis lung carcinoma growth.
a, b, Excised Lewis lung carcinoma (a) and B16/F10 melanoma (b) comparing the effects of NC
and the effects of nanocells with NC[D], L[C], co-injection of NC[D] + L[C], L[CD] and a lower
dose (ld) of NC. Control groups received saline. c, d, Tumor volume in different treatment
groups for Lewis lung carcinoma (c) and B16/F10 carcinoma (d). Results are means plusminus
s.e.m. V, vehicle. e, Kaplan-Meier survival graph showing that treatment with NC significantly
increases the lifespan: blue squares, vehicle; black triangles, NC; orange triangles, L[CD]. f, The
effect of different treatments on the white blood cell (WBC) counts. Results are means
plusminus s.e.m. Arrows represent drug administration. *P <0.05 vs. vehicle (V).
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As shown in Fig. 4, both the L[C] and NC[D] groups showed tumor inhibition compared with the
PBS-treated group. The NC[D] + L[C] treatment group had only a negligible improvement over
either of the treatments alone, which could arise from the preclusion of NC[D] after chronic
administration of the anti-angiogenic agent. In contrast, L[CD] treatment induced a greater
inhibition than NC[D] + L[C], possibly from the simultaneous release of free doxorubicin and
combretastatin. A greater exposure to the cytotoxic agent at the acute phases of the therapy,
resulting from the nonnalization of the tortuosity of tumor vessels15 , has been reported to
underlie such an outcome. Another explanation could be that low-dose (that is, 'metronomic')
chemotherapy can also exert an anti-angiogenic effect16. However, the NC-treated groups, when
compared directly with the equivalent doses of the NC[D], L[C], NC[D] + L[C] and L[CD]
groups, had a distinctly superior outcome. NC treatment-induced inhibition of tumor growth was
dose-dependent, although melanoma was more susceptible than lung carcinoma. Furthermore,
there was a significant increase in the lifespan of the NC-treated animals (Fig. 4e).
These observations bring out two issues. First, it is well known that tumor cell response
to chemotherapy is a function of the chemotherapeutic agent. As observed here, the greater
susceptibility of melanoma than the Lewis lung carcinoma to this current drug combination is
consistent with this view. Second, the effectiveness of a chemotherapeutic agent is likely to be a
function of signaling pathways and the responses to extracellular signaling from the heterotypic
environment that impinge on the tumor cells. This underscores the need to develop
chemotherapeutic approaches while keeping in perspective the different compartments of distinct
tumors.
To dissect the mechanism of action, we immunostained tumor cross-sections for an
angiogenesis marker, von Willebrand factor (vWF). As shown in Fig. 5a, c, the L[C] group
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Figure 5: Effect of nanocell treatment on tumor vasculature and apoptosis. a, Top: cross-
section of tumors immunostained for vWF, an endothelial marker. Bottom: tumors TUNEL-
labelled for apoptosis with the use of Texas red-labelled nucleotide, and co-stained with an anti-
HIF 1-alpha antibody labelled by FITC. b-d, Graphs showing tumor vessel density (b), hypoxia
(c) and apoptosis (d). Results are means plusminus s.e.m. (n = 3). Asterisk, P < 0.05; two
asterisks, P < 0.01; three asterisks, P < 0.001; all compared with controls (analysis of variance
with Newman-Keul's post-hoc test). e, Western blots showing the effect of different treatments
on the levels of HIF1-alpha and VEGF;. f, g, Graphs of levels of HIF1-alpha (f) and VEGF (g),
normalized to beta-actin; expression is shown relative to vehicle, normalized to 1. Results are
means plusminus s.e.m. Asterisk, P < 0.05 compared with other combretastatin-treated groups.
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induced a more than 50% loss in vasculature compared with PBS-treated controls. There was no
difference in the vessel density between the groups treated with L[C], L[CD], NC and the NC[D]
+ L[C]. NC[D] had no effect on the tumor vasculature, indicating that 'metronomic' dose anti-
angiogenesis was not the underlying cause for the enhanced efficacy observed with nanocells.
We next evaluated the tumors for apoptosis by using TdT-mediated dUTP nick end
labeling (TUNEL) staining, staining the same sections simultaneously for HIF 1-alpha
expression. As shown in Fig. 5a, d, e, NC[D] treatment induced significant apoptosis in the
tumor without any increase in the expression of HIF 1 -a. L[C] treatment did not induce
apoptosis, nor did it potentiate the effect of NC[D] when both were injected together. A possible
explanation for this observation could be attributed to the accumulation of HIF 1-alpha, which
can upregulate pro-survival growth factors7. In contrast, administration of NC significantly
increased the percentage of TUNEL-positive cells in the tumor in comparison with NC[D] alone,
and also disconnected the expressions of HIF 1-alpha and vascular endothelial growth factor
(VEGF) in comparison with other anti-angiogenesis-treated groups (Fig. 5e-g), possibly arising
from a focal build-up of doxorubicin inside the tumor, leading to increased apoptosis.
Analysis of the white blood cell count, which is highly susceptible to cytotoxic agents,
showed that treatment with NC resulted in the least systemic toxicity (Fig. 4f), consistent with
the intra-tumorally restricted release of the cytotoxic agent arising from the vascular shut-down.
To confirm the enhanced uptake into the tumor, we fabricated nanocells with fluorescein and
monitored the level of the dye in the tumor and other highly vascular organs. The nanocells were
detected within 5 h in all the vascularized tissues in equilibrium with the levels in the blood, and
preferential accumulation of the nanocells in the tumors was evident at 24 h, with a concomitant
fall in the serum level (Supplementary Fig. 2). This selective uptake into the tumor could arise
from increased residence time in the circulation as a result of pegylation-induced reduction in
immunogenicity1 7 . Furthermore, the unique 'leakiness' of the tumor vessels, which, unlike
physiological vasculature, have pores that are 400-600 nm in diameter1, enhances the
permeability and retention of the nanocells fabricated in this study. Additionally, the anti-
angiogenesis agent-induced decrease in hydrostatic pressure gradient across the vascular wall
could explain the increased accumulation at 24 h compared with earlier time points19. Although
further studies are needed to dissect out these effects, the reduced toxicity and enhanced anti-
tumor anti-metastatic effects (Supplementary Fig. 3) emphasizes the advantages of the
mechanism-based design of the system.
2.1.4. Conclusions
Several components of the nanocell approach can facilitate future therapy in humans.
First, the nuclear arrangement of cytotoxic agent-conjugated nanoparticle and the encapsulation
of the anti-angiogenesis agent in the surrounding phospholipid block-copolymer envelope
enables temporal targeting of the tumor vasculature, resulting in the intra-tumoral trapping of the
nanoparticles. Second, the resultant slow release and focal build-up of the cytotoxic agent within
the tumor allows a prolonged exposure and an increase in the apoptotic potential, which can
overcome hypoxia-induced reactive resistance. Third, although we show here a selective tumor
uptake, we recognize that these vehicles can be further specifically targeted to tumor vasculature
by using probes that recognize specific molecular signatures on the vasculature20 . Thus, the
nanocell concept enables a significant advance in cancer therapy over current approaches. This
platform technology supports the paradigm shift from a 'reductive' to an 'integrative' approach in
cancer therapy.
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Suppl. Figure 1. Effect of liposomal and nanocell combretastatin and long-term nanocell
therapy on tumor growth. (A) Graph shows the effect of liposomal combretastatin and
nanocells (fabricated encapsulating only combretastatin and PLGA core) were administered to
melanomabearing mice. Treatment was started when the tumors reached 50mm3 in volume and
continued every alternate day for five rounds of administration. The total combretastatin
administered per injection in either formulation was 50 mg/kg. In another experiment,
melanoma-bearin animals were treated with seven cycles of NC therapy once the tumors reached
50 mm3 in volume. Control animals were treated with PBS vehicle, and were sacrificed on day
17 as the tumors became too big in size. In the long-term treated group, 50% of the animals
showed almost complete regression of tumor over 28 days, and as shown in graph (B) the
remaining animals had significantly smaller tumor volume as compared to the untreated animals.
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Suppl. Figure 2. Nanocell Biodistribution. The graph shows the bio-distribution of nanocells
fabricated with fluorescein dye, quantified over time by measuring the levels of the dye at 5, 10
and 24 hours. At 24 hours, a preferential accumulation of the nanocells in the carcinoma was
evident in comparison to other vascularised tissues, with a concomitant fall of the levels
in blood. All data are mean ± SEM with n=3-5 per group.
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Suppl. Figure 3. Effect of nanocell therapy on metastasis of primary GFP+ melanoma to
lungs and liver. (A) Upper panel depicts a cross-section of same-level lung tissues from
different treatment groups. (B) Panel shows the same level cross-sections of livers from different
treatment groups. The organs were excised from animals treated with nanocells (NC),
doxorubicinconjugated nanoparticles NC[D], liposomal-combretastatin (L[C]), or co-injected
with NC[D]+LC, or doxorubicin and combretastatin encapsulated liposomes (L[CD]). Control
groups were treated with saline. The tissues were fixed in 4% paraformaldehyde on ice, and
stained with standard H&E. The images were captured using a Zeiss LSM5 10 confocal
microscope. The fluorochromes were excited with 488 nm and 543 nm laser lines, and the
images were captured using 505-530 BP and 565-615 BP filters at a 512x512 pixel resolution.
The merge images shown here demonstrate distinct metastatic nodes, which appear yellow. The
graph depicts the quantification of metastatic nodes in each view field. Data expressed are mean
± SEM from n=3. ***P<0.001 vs controls (ANOVA with Newman-Keul's Post Hoc test).
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Suppl. Figure 4. Doxorubicin to PLGA 5050 conjugation schematic. Schematic showing the
detailed synthetic steps involved in the conjugation of Doxorubicin to PLGA 5050.
Supplementary Methods
Conjugation of doxorubicin to PLGA.
Polylactic glycolic acid (PLGA) (Medisorb@ 5050 DL 4A), having a lactide / glycolide
molar ratio of 50/50, was obtained from Alkermes (Wilmington, OH). The average molecular
weight of this polymer is reported to be 61 kDa and it has free hydroxyl and carboxylic groups at
its terminal ends. Doxorubicin hydrochloride, pnitrophenyl chloroformate and triethylamine
were obtained from Sigma-Aldrich (St.Louis, MO). Briefly, 1.5 g of PLGA 5050 DL 4A was
dissolved in 15 ml of methylene chloride and activated by the addition of 14 mg of p-nitrophenyl
chloroformate and 9.4 mg (~ 9.6 pL) of pyridine to the solution, kept in an ice bath at 0 'C
(stoichiometric molar ratio of PLGA: p-nitrophenyl chloroformate: pyridine = 1:2.8:4.7). The
reaction was carried out for 3 hours at room temperature under nitrogen atmosphere. The
resulting solution was diluted with methylene chloride and washed with 0.1 % HCl and brine
solution. The organic phase was separated, dried on anhydrous magnesium sulfate, filtered, and
then rotary-evaporated to yield activated PLGA polymer. Activated PLGA (0.4g) was dissolved
in 3 mL of dimethylformamide (DMF) and reacted with 4 mg of doxorubicin and 2.7 mg (~ 4
pL) of triethylamine for 24 hours at room temperature under nitrogen atmosphere (stoichiometric
molar ratio of activated PLGA: doxorubicin: triethylamine = 1:1:4). The final conjugated product
as precipitated by the addition of cold ether, washed with ether, filtered, and dried under vacuum.
The detailed schematic of the synthetic process is elucidated in Supplementary Figure 4. The
conjugation of doxorubicin to PLGA increased the loading efficiency from less than 1% (non-
conjugated) to over 70%.
Synthesis and scanning electron microscopic analysis of the nanoparticles.
Nanoparticles were formulated using an emulsion-solvent evaporation technique as
described. Briefly, 50mg PLGA-DOX was allowed to dissolve completely in 2.5mL acetone for
one hour at room temperature. At this time, 0.5mL methanol was added and the entire solution
was emulsified into an aqueous solution of PVA (0.5 g / 25 mL) by slow injection with constant
homogenization using a tissue homogenizer followed by one minute of sonication (Misonix,
Farmingdale, NY). The emulsion was added to a dilute aqueous solution of PVA (0.2 g / 100
mL) with rapid mixing for 3 hours at room temperature to evaporate any residual acetone or
methanol. Nanoparticle size fractions were recovered by ultracentrifugation at 10000, 25000 and
50000 xg. Nanoparticles from the smallest size fractions were extruded through a 100nm
membrane using a hand-held extruder (Avestin, Ottawa, ONT) to obtain nanoparticles for
encapsulation within nanocells. The nanoparticles were sized by dynamic light scattering
(Brookhaven Instruments Corp, Holtsville, NY) as well as by scanning electron microscopy
(SEM). For SEM, the nanoparticles were dried for 72 hours, following which a small quantity
was dusted onto a carbon grid and coated with gold. They were analyzed using a Jeol JSM5600
EM at a magnification of 3700X.
Synthesis of nanocells
To prepare the lipid envelope of the nanocell, cholesterol (CHOL),
eggphosphatidylcholine (PC), and distearoylphosphatidylethanolamine - polyethylene glycol
(m.w. 2000) (DSPE-PEG) were obtained from Avanti Polar Lipids (Birmingham, AL).
Combretastatin A4 was obtained from Tocris Cookson (Ellisville, MO). All other reagents and
solvents were of analytical grade. PC:CHOL:DSPE-PEG (2:1:0.2 molar) lipid membranes were
prepared by dissolving 27.5mg lipid in 2 mL chloroform in a round bottom flask. Combretastatin
A4 (12.5 mg) was co-dissolved in the choloroform mixture at a 0.9:1 drug:lipid molar ratio.
Chloroform was evaporated using a rotoevaporator to create a monolayer lipid/drug film. This
film was resuspended in 1 mL H20 after one hour of shaking at 65 *C to enable preferential
encapsulation of combretastatin A4 within the lipid bilayer. When synthesizing nanocells,
nanoparticles containing 250ig doxorubicin were added to the aqueous lipid resuspension
buffer. The resulting suspension was extruded through a 200 nm membrane at 65 'C using a
hand held extruder (Avestin, Ottawa, ONT) to create the lipid vesicles. The average vesicle size
was determined by dynamic light scattering (Brookhaven Instruments Corp, Holtsville, NY).
Transmission electron micrographs
The nanocells were fixed in 2.5% gluteraldehyde, 3% paraformaldehyde with 5% sucrose
in 0. 1M sodium cacodylate buffer (pH 7.4), embeded in low temperature agarose and post fixed
in 1% OsO4 in veronal-acetate buffer. The sample was stained in block overnight with 0.5%
uranyl acetate in veronal-acetate buffer (pH6.0); then dehydrated and embedded in epon-812
resin. Sections were cut on a Leica ultra cut UCT at a thickness of 70nm using a diamond knife,
stained with 2.0% uranyl acetate followed by 0.1% lead citrate and examined using a Philips
EM410.
Physicochemical release kinetics studies
Concentrated drug-loaded nanocells were suspended in 1 ml of PBS or hypoxic cell
lysate buffer, and sealed in a dialysis bag (M.W. cutoff: 10,000, Spectrapor). The dialysis bag
was incubated in 20 ml of PBS buffer at 37C with gentle shaking. 200 ul aliquots were taken
from the incubation medium at predetermined time intervals and stored frozen for analysis.
Released drug was quantified by reverse phase HPLC using a C18 column (4.5 mm X 150 mm,
Waters) with acetonitrile (A) and water (B) as eluents. Starting conditions were 80% A and 20%
B with a linear gradient over 15 min to 10% A and 90% B, a linear gradient over five minutes to
0% A and 100% B, and a linear gradient over 5 min returning to the start conditions with a flow
rate of 1 ml/min. A standardized amount of dexamethasone was added as an internal control for
absolute quantification of combretastatain A4 and doxorubicin. Combretastatin A4 and
dexamethasone were detected by wavelength monitoring at 295 nm and doxorubicin was
detected by wavelength monitoring at 480 nm. The amount of free doxorubicin released is small
as compared to the doxorubicin-PLGA fragments, emphasizing that free doxorubicin and the
active doxorubicin-PLGA fragments, and not doxorubicin-PLGA oligomers, contribute to the
cytotoxic effect.
In vitro co-culture assay
To dissect out the anti-angiogenesis actions from the anti-tumor activity, we developed a
co-culture assay mimicking the tumor milieu. B 16/F10 melanoma cells were transfected to
express green fluorescent protein (GFP), and selected under puromycin pressure. Colonies (GFP-
BL6/F 10) were confirmed to express GFP using epifluorescence microscope and fluorescence
activated cell sorting, and cultured in MEM-a medium supplemented with 10% fetal bovine
serum. Since isolating primary tumor endothelial cells entails practical difficulties, we used
human umbilical vein endothelial cells, which are widely used in angiogenesis studies. Human
umbilical vein endothelial cells (Cambrex, pooled cells from 3 donors) were cultured in EBM
media (Clonetics) supplemented with bullet kit (Clonetics) and 20 % FBS. For the co-culture
assay, growth factor reduced Matrigel (extracellular matrix from EHS carcoma) was plated on
glass coverslips, and allowed to gel at 37 degree Celcius. HUVECs were trypsinised and plated
on the Matrigel at a density of 30000 cells per coverslip/well of a 12 well plate, and allowed to
form tube-like structures over a period of 24 hours. At this time point, GFP-BL6/F10 cells were
added to each well at a density of 10,000 cells/well. The co-culture was allowed to develop for a
further 24 hours, following which the appropriate treatments were started. At the end of defined
periods of incubation, the cells were fixed with 4% paraformaldehyde on ice, and incubated with
propidium iodide to label the nuclei. The coverslips were washed with phosphate buffer saline,
and analysed using a Leica LSM5 10 confocal microscope. Images were captured randomly from
four sectors. The fluorochromes were excited with 488 nm and 543 nm laser lines, and the
images were captured using 505-530 BP and 565-615 BP filters at a 512x512 pixel resolution.
Merge images were created by combining images from both the filters, where the melanoma
cells fluoresced yellow while the endothelial cells were red. Quantification of the area covered
by endothelial cells or GFP-BL6/F 10 cells was carried out using a planimetric point-count
method using a 224-intersection point square reticulum. Data were expressed as the ratio of each
component to the total area covered by cells.
In vivo tumor model
Male C57/BL6 mice (20 g) were injected with 3x105 GFP-BL6/Fl0 or 2.5x 105 Lewis
lung carcinoma cells into the flanks. The growth of the tumors was monitored regularly. The
mice were randomized into different treatment groups when the tumor reached 50mm3 in
volume. Each formulation, nanocell or simple liposomes, was prepared, quantified, and diluted
such that 100pl of administration was equivalent to 50 mg/kg and 500pjg/kg of combretastatin
and doxorubicin respectively. The rationale to encapsulate the doxorubicin-nanoparticle within
the lipids to generate the NC[D] group was to remove any sizing bias, and also to maintain the
uniformity in pegylation between groups, such that the pharmacokinetic profile remained
unaltered. We used L[C] as a control group as a simple liposomal formulation of combretastatin
could later be translated into clinical applications. Furthermore, a comparison of the liposomal
combretastatin (L[C]) and nanocells with only combretastatin (NC[C]) demonstrated that both
the treatment groups exerted similar effects on tumor inhibition (Supplementary Figure lA),
indicating that alone the PLGA-core of the nanocell was inactive. The animals were injected
every alternate day after the tumors reached the desired size. The animals were sacrificed on day
17, and the tumors were excised for histopathology. Simultaneously, 1 ml of blood was drawn
through cardiac puncture, and analyzed for toxicity profile of the treatment regimens.
Immunohistocytochemistry for tumor vasculature
Tumor samples were embedded in TissueTek and snap frozen on dry ice. Thin
cryosections (10 pim) were made using a Reichart cryostat, and fixed in methanol. The sections
were then permeabilised in Tris buffer saline with Triton X and Tween, and blocked with 1%
goat serum. The sections were probed overnight with a rabbit primary antibody against
vonWillebrand factor (Dako, 1 in 2000 dilution), an endothelial cell marker. The staining for
vWF was found to be consistent with the expression of other endothelial markers such as VE-
cadherin and Tie-2 (data not shown). The sections were washed and re-probed with a goat
secondary antibody coupled to Texas Red. The sections were coated with slowfade (Molecular
probes), and imaged using a Leica LSM5 10 confocal microscope. Images were captured
randomly from three areas per section. The fluorochromes were excited with 488 nm and 543 nm
laser lines, and the images were captured using 505-530 BP and 565-615 BP filters at a 512x512
pixel resolution. Vessel density was quantified using stereological approaches, using a
planimetric point-count method using a 224-intersection point square reticulum.
Quantifying apoptosis and HIF1 a in the tumor sections
Tumor cryosections were prepared as described above. The sections were processed for
TUNEL staining using Texas red labeled nucleotide as per the manufacturer's instruction
(Roche). The sections were then permeabilised in Tris buffer saline with Triton X and Tween,
and blocked with 1% goat serum. The sections were probed overnight with a primary antibody
against HIFla. The sections were washed and re-probed with a goat secondary antibody coupled
to FITC. The sections were coated with slowfade (Molecular probes), and imaged using a Leica
LSM5 10 confocal microscope. The sections were coated with slowfade (Molecular probes), and
imaged using a Leica LSM5 10 confocal microscope. Images were captured randomly from three
areas per section. The fluorochromes were excited with 488 nm and 543 nm laser lines, and the
images were captured using 505-530 BP and 565-615 BP filters at a 512x512 pixel resolution.
Apoptosis and hypoxia was quantified using stereological approaches, using a planimetric point-
count method using a 224-intersection point square reticulum.
Analysis of metastatic nodes
Since melanoma has the potential to metastasize to the lungs and the liver, we evaluated
the effect of different treatments on pulmonary and hepatic metastatic potential of the primary
tumor. In contrast to control mice, treatment with nanocells displayed little or no visible tumor
metastasis, achieving a significantly superior outcome than other treatment group
(Supplementary Figure 3). A possible explanation for this behavior is that the prolonged
exposure to the cytotoxic agent following the vascular collapse resulted in an overall decrease in
the expression of HIF 1 a and related growth factors (Figure. 4) These organs were harvested
from the animals during necropsy, and fixed in 10% formaldehyde. The tissues were then
paraffin embedded, and thin section slides were prepared for H&E staining. The slides were
imaged with a Leica LSM5 10 confocal microscope. The fluorochromes were excited with 488
nm and 543 nm laser lines, and the images were captured using 505-530 BP and 565-615 BP
filters at a 512x512 pixel resolution. Metastatic nodes were quantified by counting the number
of yellow foci per section in the merged image.
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2.2. Lipid-Encapsulated Quantum Dots Distinguish Tumor and Normal Vasculature
2.2.1. Introduction
As tumors undergo rapid growth, they must generate their own vascular network in order
to provide the nutrients necessary for continued expansion and spread. In vivo imaging of tumor
vascularization is now of paramount importance, as this is both a sign of increasing tumor
malignancy and a potential target for new therapies. We demonstrate here a method for imaging
and specifically identifying tumor-specific vasculature using quantum dots encapsulated within
sterically stabilized liposomes, combining the fluorescent properties of quantum dots with the
bioavailability and tumor-specific interstitial uptake of the liposomal vehicle.
Quantum dots have emerged as a powerful alternative tool for fluorescence imaging due
to a unique set of physiochemical properties that surpass those of fluorescent dyes in many
biomedical applications. These include a narrow fluorescent emission under a broad set of
absorption spectra (thus allowing the detection of multiple quantum dots with a single absorption
wavelength), improved resistance to photobleaching and chemical degradation, and the
availability of quantum dots to a multitude of chemical conjugation and capping strategies .
Fluorescent labeling with quantum dots has successfully enabled measuring the ability of
particles to access the tumor microenvironment2, tracking of cancer cells undergoing metastasis3,
in vivo imaging of capillary structures hundreds of micrometers beneath the skin4 , as well as a
multitude of additional successful biomedical applications. Quantum dots are particularly well
suited for in vivo applications as they may remain fluorescent in tissue structures for at least four
months5 , and their large two-photon cross-sectional efficiency allows high resolution intravital
microscopy of deep tissue structures at the subcellular level6 .
2.2.2. Materials and Methods
Liposome preparation
1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC), 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] (DSPE-PEG2000) and
Cholesterol (CHOL) were obtained from Avanti Polar Lipids (Alabaster, Al). A lipid mixture
consisting of DSPC:CHOL:PEG-DSPE (2:1:0.2 molar ratio) was prepared by dissolving the
lipids in chloroform in a round-bottomed flask (10 pimol total lipid). The solution was frozen in
liquid nitrogen for 3 min and lyophilized overnight. Quantum dot loaded liposomes were
prepared by hydrating the lyophilized lipid mixtures with 0.3 ptM Amino-PEGylated,
derivatized-polyacrylic acid coated cadmium selenide/zinc sulfide core/shell quantum dots
(Quantum Dot Corporation, Hayward CA) and 1 ml of buffer solution 10 mM Tris-HCl with 150
mM NaCl at pH 7.4 via five freeze-thaw vortex cycles. These multilamellar liposomes were then
extruded 10 times through 0.1 pim polycarbonate membranes filters at 50 'C to produce large
unilamellar liposomes. Unentrapped quantum dots were removed from the liposome suspension
by passing it through a Sephadex G-50 column equilibrated with a 150 mM NaCl solution.
Electron microscopy
Sample was negatively stained by absorbing material on a formvar/ carbon coated nickle
grid. Grid was washed with 2% Uranyl Acetate and dried. Images were taken on a Philips
EM410 transmission electron microscope.
Localization of quantum dots in vivo.
Male C57/BL6 mice (20g) were injected with 2.5x105 Lewis lung carcinoma cells into
the flanks. The growth of tumors was monitored regularly. Encapsulated quantum dots were
injected into Lewis lung carcinoma-bearing mice. Cross sections of tissues (30 mm) harvested at
10 and 24 h post-treatment were immunostained for vWF to delineate the blood vessels. Images
were captured using a LSM5 10 confocal microscope, with excitation at 488 nm and emission for
FITC (vWF) and Rhodamine (Qdots). 3D reconstruction of the tissue sections was also
performed to show depth-coding intensity for vWF and quantum dots.
2.2.3. Results and Discussion
Quantum dots have previously been employed as labels for normal and neoplastic blood
vessels utilizing synthesis and targeting protocols designed for efficient internalization within the
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vascular structures' . We explored here an alternate approach to targeting tumor vasculature,
using a macromolecular liposome-based carrier in order to reach the appropriate size that
maximizes extravasation through porous tumor vasculature and restricts nonspecific passage
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through healthy vasculature or significant uptake by non-tumor bearing tissue' . We
investigated whether the "leakage" of quantum dot fluorescence into the tumor interstitium
would provide an effective platform for not only imaging angiogenic vessels, but also for readily
distinguishing tumor-specific and normal vasculature in vivo.
Tumor-specific vasculature exhibits marked structural abnormalities compared to normal
vasculature including increased tortuosity, excessive branching, and aberrant basement
membrane formation. Tumor vasculature also has a high vascular permeability, or porosity.
This porosity is a result of the presence of numerous 'openings' as large as 600 nm (including
endothelial fenestrae and transcellular holes) in the vascular wall which permit the passage of
nanoscale particles from the bloodstream into the tumor interstitium. This porosity in
combination with decreased tumor lymphatic drainage enables significantly increased tumor
uptake and retention (the EPR effect) of agents associated with macromolecular delivery
vehicles9 .
The extent of tumor vascularization is further correlated with metastatic potential, tumor
drug efficacy, and overall patient survival 0 , making an effective means of identifying and
imaging angiogenic vessels critical both as a diagnostic and therapeutic tool. A number of
different modalities are currently being assessed for imaging angiogenic vessels, including
magnetic resonance imaging, computed tomography, ultrasound, and positive emission
tomography based protocols". Additionally there are a number of fluorescence-microscopy
based techniques for imaging angiogenesis including the use of fluorescent liposomes, dextrans,
nanospheres, and viral nanoparticles 2 . These fluorescent approaches are particularly
advantageous as they do not rely on the use of specialized medical imaging equipment not
readily accessible in many research laboratories.
We encapsulated hydrophilic quantum dots within large unilamellar sterically stabilized
liposomes (Fig.1). The utility of this delivery system was tested in Lewis lung carcinoma
bearing mice. Spleen, lung, liver, and tumor samples were harvested from these animals at
various time posts post intravenous injection of the quantum dot formulations(Fig.2D). Confocal
imaging of the tissue sections indicates that quantum dots were spatially restricted within the
vasculature in physiologically normal tissues (lungs, liver and spleen) at 24 hours. In contrast
significant extravasation into the tumor interstitium was observed at the same time point, which
was confirmed with 3D confocal-reconstruction of the tissue sections (Figure 2).
Previous methods for delivering quantum dots in vivo have included surface
functionalization with water soluble ligands or silanization 1. Block-copolymer micelles and
lipid nanoparticles have also been successfully used as delivery vehicles for in vivo imaging' 1.
A recent study explored tumor uptake of quantum dots entrapped in a ~1 00nm lipid nanoparticle
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after i.p. administration . In contrast to these studies, here we capitalized on the size and the
propensity of sterically-stabilized liposomes to use the EPR effect for homing specifically to the
tumor after i.v. administration. This is consistent with extensive reports that have demonstrated
that sterically stabilized liposomes greater than 100 nm in size preferentially accumulate within
the tumor interstitum. Delivering quantum dots in vivo via liposomal encapsulation is
particularly advantageous as these vehicles are well suited for delivering both hydrophilic and
hydrophobic particles 7' 17. Further, we have shown previously that the delivery of multiple
agents from multi-compartmental lipid vesicles in a spatial-temporal manner can result in a
significantly enhanced therapeutic effect' 8 . These vehicles may then be suitable for delivering a
combination of fluorescent quantum dots for imaging tumor angiogenesis with anti-cancer
therapeutic agents for treating the neoplasm.
2.2.4. Conclusion
The cytotoxicity of quantum dots in clinical practice is still under investigation, and
conclusions are complicated by the variety of published synthesis and functionalization
protocols'. Most studies thus far do not report adverse effects on cell function or development
over the short term, though long-term cytotoxic studies are needed before definitive conclusions
can be drawn. Liposomal delivery vehicles prevent the need for additional potentially cytotoxic
quantum dot synthesis regimens necessary for bioavailability or targeting. The ability to load
multiple quantum dots per targeting vehicle also enables better control over the concentration of
quantum dots at the target site.
In conclusion, we present here the first study demonstrating the use of sterically
stabilized liposome- encapsulated fluorescent quantum dots for distinguishing normal and
neoplastic vasculature. The clear delineation between the spatial distribution of these
formulations between tumor and normal vasculature creates the exciting opportunity to harness
this approach in detection of solid tumors.
Figure 1. Imaging of Angiogenic Vasculature. A. A Transmission electron micrograph
depicting a nanoscale (-100 nm) sterically-stabilized liposome entrapping quantum dots. The red
arrow outlines the lipid coat. Sample was negatively stained by absorbing material on a formvar/
carbon coated nickle grid, stained with uranyl acetate, and imaged using a Philips EM410. B and
C. Confocal images of cross sections of lungs and liver respectively from mouse that were
injected with pegylated quantum dots without the liposomal entrapment, which clearly shows
that the fluorescence signal from the QDs are widely distributed in both the tissues.
-0
Figure 1. Imaging of Angiogenic Vasculature. D. Confocal micrographs of tissue cross
sections harvested from tumor-bearing mice at 10 and 24 h post-injection with liposome-
entrapped QDs. The sections were immunostained for von Willebrand Factor (vWF) to delineate
vasculature. Images were captured using a Zeiss LSM510 Confocal microscope at 512x512 pixel
resolution. The sections were excited with a 488nm laser, and emission was absorbed at FITC
(vWF) and Rhodamine (QD) wavelengths. The signals from the vasculature and the QDs were
merged to study the spatial distribution of the quantum dots with respect to normal and tumor
vasculature.
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Figure 2. 3-D Depth Coding. The confocal sections through the liver and tumor tissues were
merged in a 3D reconstruction to create depth-coding of intensity for vWF and quantum dots
within the excised tissue sections. The liposome-entrapped QDs were found to be spatially
restricted within normal vasculature but extravasate out from the tumor vasculature at 24h.
vWF
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2.3. A voxel-based Monte Carlo Model of Drug Release From Bulk Eroding Nanoparticles
2.3.1. Introduction
The use of polymeric nanoparticles as drug delivery devices is becoming increasingly
prevalent in a variety of therapeutic applications. Despite their widespread clinical use, the
factors influencing the release profiles of nanoparticle-encapsulated drugs are still not
quantitatively understood. We present here a new, semi-empirical model of drug release from
polymeric nanoparticles using a formulation of dexamethasone encapsulated within poly(lactic-
co-glycolic acid) PLGA to set model parameters. We introduce a three-dimensional voxel-based
framework for Monte Carlo simulations that enables direct investigation of the entire spherical
nanoparticle during particle degradation and drug release. Due to implementation of this model
at the nanoscale, we utilize assumptions that simplify the model while still allowing multi-phase
drug release to be simulated with good correlation to experimental results. In the future,
emerging mechanistic understandings of nanoparticle drug release may be integrated into this
simulation framework to increase predictive power.
The shift from micro- to nano- scale drug delivery systems in recent decades has been
driven by improvements in polymer formulation technology and evidence that medical
applications such as chemotherapy are significantly enhanced by the use of nanoscale delivery
vehiclesi,2 3 4 . Because drug release profiles differ based on the polymer, drug, and design
parameters, the availability of computational models to understand and predict drug release is
valuable for the extension and optimization of existing drug delivery technologies.
Several models have been reported in the literature to describe drug release and particle
breakdown for polymer-based delivery vehicles' 6'','. It is clear from these studies that the
number of factors influencing drug release is too unwieldy for a single model to incorporate.
Such factors include water and drug diffusion, drug dissolution, polymer molecular weight,
particle size and geometry, polymer degradation, micro-environment pH changes, autocatalysis,
polymer swelling, and more'1'. Incorporation of these factors is further complicated by a still
incomplete understanding of the extent to which they each influence the kinetics of drug release.
Previous modeling approaches have been limited by necessity to incorporating the factors most
influential to drug release or polymer breakdown for a particular delivery system 0 . Despite this
limitation, computational models have still successfully simulated complex multi-phase drug
release profiles from polymeric microparticles 12,13,14, . Few studies have extended these models
16to polymeric nanoparticles, though these are becoming prominent in therapeutic applications
The mechanism of drug release from nanoparticles may differ from that of microparticles
even when both vehicles have the same polymer composition. Drug diffusion through the
polymer matrix has been shown to be slower in nanoparticles than in microparticles, and this
may be due to more dense internal structures as a result of fabrication techniques or the
neutralization of autocatalysis-enhanced diffusion phenomenon at the smaller length scales' 9 ' 7.
For the purposes of our model, we postulate that the reduced drug diffusivity in nanoparticles
limits the influence of diffusion in the model to the interface between polymer and the external
aqueous environment. That is, we assume that drug release occurs only after degradation of
surrounding polymer and the formation of an erosion channel to the particle surface. Once the
drug diffuses into the exposed erosion channel, the drug is considered to be released due to the
small distances necessary to travel to the particle surface at the nanoscale. Using this
framework, we model drug release from bulk eroding nanoparticles based upon a three
dimensional Monte Carlo simulation of polymer erosion.
2.3.2. Results and Discussion
For the Monte Carlo simulation presented here, entire spherical nanoparticles are
represented using voxels. A voxel is the volume element which represents data on a regular grid
in three dimensional space and is analogous to a pixel which is the area element representing
data in two dimensions. Previous two dimensional models have depicted drug release from a
pixel as dependent upon the state of the pixel's immediate 8 neighbors '". In this three
dimensional voxel-based model, we assess the influence of the 18 neighbors most immediately
surrounding the voxel in order to give the best representation of a sphere (Fig. 1). The State
Diagram (Fig. 2) describes the simulation algorithm governing voxel dynamic state transitions
(xij,k) and voxel drug release. Assuming a homogeneous mixture of drug and polymer, each
voxel begins with a voxel dynamic state (xi,k) of 1. The lifetime of individual voxels follows a
Poisson's distribution given by:
TLi j,k(t) = -ln(c/k)
where F is a random number and 1/k is the half life of the polymer system. Expiration of this
lifetime changes the voxel dynamic state (xi ,k) to zero and the polymer is considered degraded.
In order for the polymer to be considered eroded, access to the aqueous environment via an
erosion channel from the surface of the nanoparticle is required. Such a channel is formed when
at least one of the 18 immediate neighboring voxels is eroded, i.e. any of the neighbor's dynamic
voxel state (xij,k) becomes -1.
We formulated PLGA nanoparticles encapsulating the hydrophobic agent dexamethasone
as described in Fig. 3. Hydrolysable polymers such as PLGA are often used in the formulation
of nanoparticles as they combine sustained drug release with complete biodegradability' 9. The
polymer half life (1/ k) is approximated at 0.121 days from previous measurements in the
literature2 0. In order to run the model simulation, we used the drug release data from this
formulation to fit values for two parameters: the number of voxels (N) that compose each
nanoparticle and a parameter (K) that integrates the influence of mass transport phenomenon into
the simulation. The parameter K (value between 0 and 1) measures the likelihood of drug release
from an intact voxel into an aqueous erosion channel upon exposure, and represents the
combined contributions of drug diffusion and dissolution on drug release at this interface. The
parameter N is related to the physical size of the particle and also controls the surface area to
volume ratio. Polymeric nanoparticles have a higher surface area to volume ratio than
microparticles which may lead to a more pronounced relative initial burst of drug release.
The experimental release profile of dexamethasone from PLGA nanoparticles shows an
initial burst release of 40% over the first -25 hours. A more sustained phase of drug release
occurs over the next -120 hours resulting in complete release of encapsulated drug by 150 hours.
The model simulation was a good match to experimental drug release with a coefficient of
determination (R2) value of 0.98 (Fig. 3). We are also able to use our model simulation to
investigate physical properties of the voxelated nanosphere during erosion by exploring the
fragment size distribution and average size of the nanoparticles over time (Fig. 4a). Percolation-
driven particle breakdown due to bulk erosion is shown to occur after 150 hours, and so does not
appear to play a dominant role in drug release. A plot of nanoparticle surface area / volume with
respect to time (Fig. 4b) indicates an initial lag prior to the formation of erosion channels. This
corresponds well with the lag before the change in phase of experimental drug release from
initial burst to sustained release (Fig. 3).
The potential of extending this model to additional drug formulations is explored through
variation in the parameter K (Fig. 5). The influence of K is restricted to drug release at the
interface of polymer and the external aqueous environment. A K value of 1 corresponds to
immediate drug release from an exposed intact voxel into an erosion channel, and the resultant
rapid drug release profile is consistent with that of a highly hydrophilic drug2 1 . A K value of 0
indicates that drug release from an exposed intact voxel does not occur until the voxel is
degraded, and the resultant sustained drug release profile is consistent with that of a polymer-
conjugated drug. Values of K between 0 and 1 correspond with intermediate capacities for drug
release from an exposed intact voxel, and the resultant multi-phase drug release profiles are
consistent with that of a hydrophobic drug as presented here.
2.3.4. Conclusion
Because all processes that influence drug release are not yet quantitatively understood,
there is value to the use of semi-empirical computational models able to simulate multi-phase
drug release profiles. Use of the model presented here does not require knowledge of physical
parameters such as polymer porosity, drug solubility, and drug diffusivity which are often not
available or can be difficult to measure. Voxelation of the entire nanoparticle facilitates the
extension of this platform to non-symmetrical vehicle formulations as well as non-uniform drug
and polymer distributions. Variation of the parameter K demonstrates the versatility of this
model for simulating release of hydrophilic, hydrophobic, and polymer-conjugated drugs. This
model was intended as a proof of principle, however in the future emerging mechanistic
understandings of phenomenon influencing nanoparticle drug release may be incorporated to
further increase accuracy and strengthen predictive power.
Figure 1: Geometric implications of pixel and voxel neighborhoods. The distance (d)
between the center of a pixel (in 2D) or voxel (in 3D) and the center of its immediate neighbors
is 'lI or 12 or 13 units. The center to center distance factor (CCDF) and spherical volume ratio
(SVR) are used to calculate the neighborhood (n) that best approximates a circle (or a sphere)
enclosed within the 2D pixel (or 3D voxel) grid. A schematic representation of the
neighborhoods is depicted with the pixels/voxels colored black (center), red (d = '1), blue (d =
I2) and green (d = 13).
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Figure 2: Flowchart and state diagram governing the voxel-based model. An illustration of
the principles involved in estimation of voxel state transitions, nanoparticle fragmentation and
drug release. A visualization of polymeric nanoparticle bulk erosion is also depicted.
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Figure 3: Dexamethasone release from PLGA nanoparticles in vitro. Nanoparticles were
formulated using a modified emulsion-solvent evaporation technique 2,24. Briefly, 25 mg of
dexamethasone and 50 mg of PLGA were allowed to dissolve completely in 2.5 mL acetone
before addition of 0.5 mL methanol and emulsification into an aqueous 2% PVA solution with
sonication. Nanoparticles were separated from free drug by ultracentrifugation and were
demonstrated to have a mean particle diameter of 115 nm by dynamic light scattering. Drug
release was quantified by HPLC after dialysis against PBS at 37 C with gentle shaking.
Simulations of drug release were coded using the C programming language and were performed
100 times with mean values shown. The Monte Carlo simulation demonstrates good correlation
with experimental data with R2 = 0.98. Parameters: N = 5497 voxels, K = 0.5.
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Figure 4: Simulation of drug release and nanoparticle fragmentation. a. Model
representation of nanoparticle fragmentation: black scatter represents variability between
different simulations, blue line represents average fragment size. b. Simulation results for
surface area (exposed voxel area) and volume (voxel count) during nanoparticle fragmentation.
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Figure 5: Influence of the model parameter K on drug release. Simulation results for K
values between 0 and 1 demonstrate the capacity of the model for simulating the release of drugs
with distinct diffusion and dissolution characteristics. Model parameters: N = 5497 voxels,
iterations = 100.
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2.4. Structure-function Relationships of Novel Carbohydrate-Based Therapeutic Agents
2.4.1. Introduction
It is our hope that the development of novel therapeutic compounds with utility both as
structural and bioactive components will lead to more efficient nanocells with rapid clinical
application. One class of therapeutic agents that holds promise for this role is modified pectin.
Pectin is a major component of all primary cell walls and consists of a complex carbohydrate
network composed predominantly of galacturonic acid rich polysaccharides.
This complex pectin matrix may be fragmented via temperature, pH, or enzymatic
modification into shorter, soluble oligosaccharide chains. One method of fractionating pectin
has led to a subpopulation of pectin fragments with anti-tumor activity. These shorter pectin
chains dissolve more readily in water and it is believed that they contain polysaccharides having
affinity for cell-surface galectin-3 1. Galectins are a family of animal lectins defined by their
ability to recognize p-galactose and by conserved amino acid residues within the carbohydrate
recognition domains. Currently 15 mammalian galectins have been identified, with several
implicated in regulation of tumor apoptosis, inflammation, and immune escape2 . Modified
pectins have demonstrated therapeutic benefit for inhibiting tumor growth, adhesion, metastasis,
and angiogenesis in several tumor models over the past decade including melanoma3 4, breast
cancer5 , and colon cancer 6 , and one pilot phase II human clinical trial for prostate cancer7 . The
cheap, ready availability of pectin in combination with a virtual total lack of negative side effects
has made understanding the mechanism of action of these intriguing new anticancer molecules of
critical importance.
The proposed therapeutic mechanism is currently that pectin inhibits tumors through its
binding to galectin-3 8. No direct mechanism has yet been elucidated, and this is probably due to
multiple considerations. First, the temperature and pH modifications used to generate anti-tumor
pectin are likely dependent upon the pectin starting source. Pectins obtained from major
research laboratory vendors have considerable batch-to-batch variability in methods of isolation,
and so can be expected to have substantial variations in starting structure. Because pectin is so
diverse in terms of structure both within and between samples, it has so far been a substantial
challenge to identify structure-function relationships relating pectin structure and anti-tumor
activity. Second, while galectin-3 appears to play a probable role in pectin mediated anti-tumor
activity, the mechanism of action may not be entirely due to this galectin. Additional galectins,
including galectin- 19, 10, have established roles in regulating tumor apoptosis, angiogenesis, and
immune escape, and also have affinity for residues present within the complex polysaccharide
environment of the pectin matrix
We demonstrate here an integrative approach for the standardization and structure-
function analysis of a new class of anti-tumor modified pectins classified here as activated citrus
pectin (ACP) obtained by a new methodology from a consistent source of native citrus pectin
(NCP) isolated directly from lemon. We incorporate complementary analytical techniques to
link ACP structure with binding to tumor galectin targets. We further provide evidence for a
mechanism of action by elucidating key constituents of an ACP-induced anti-tumor intracellular
signaling cascade. A better understanding of ACP anti-tumor activity as it relates to its structural
modification will allow the synthesis of more effective and more reliable anti-tumor pectin
agents.
2.4.2. Materials and Methods
Preparation of pectins
NCP was isolated from lemon peels by a modification of a published procedure
Briefly, albedo was separated from fresh lemon peels and pectin was isolated under conditions of
high heat and pressure. After cooling, pectin was filtered and precipitated. The pectin pellet was
dissolved in distilled water and lyophilized. Pectin extract (NCP) was incubated with base at
high temperature. The resulting pectin contained low molecular weight pectic epitopes classified
here as ACP. For use in sterile biological assays, the pH of pectin samples was increased to 6.5
and samples were filter sterilized.
Capillary electrophoresis
Pectins (40 ptL, 20 pg) were partially depolymerized by incubation with 200 mM TFA at
80 0C for 72 h. The resulting hydrolysates were lyophilized and resuspended in 30 uL of 60 mM
sodium acetate (pH 5) containing 3 mM CaCl2. Two uL of dialyzed pectinase mixture (Sigma,
0.3 U / mL) were added and sample was incubated for 48 hours at 45 *C to achieve full
depolymerization2 1 . The pectinase reaction products were lyophilized and labeled with 8-
aminopyrene-1,3,6-trisulfonic acid trisodium salt (APTS) according to a modified procedure.
Briefly, 15 uL of 25 mM APTS in 15 % acetic acid and 5 uL of 1 M NaBH3CN were added to
dry pectin powder. The mixture was incubated at 55 *C for 90 min before stopping the reaction
by adding 500 uL of distilled water. Monomeric carbohydrate standards representing the
composition of pectin were also labeled with APTS as described. Capillary electrophoresis
analysis of APTS-labeled pectin components was performed with a ProteomeLab PA 800
(Beckman-Coulter Inc.) with a 40 cm bare-fused silica capillary (Polymicro Technologies)
running 42 mM sodiumtetraborate (pH 10.2) with Ar laser detection.
1H-NMR
1H-NMR was performed at 80 oC using a Bruker 400 MHz instrument with an average
of 256 measurements. Sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP) (Cambridge
Isotope Laboratories Inc.) was used as a reference. Pectin was prepared for NMR by
lyophilization and resuspension in D20. Pectin concentrations were 10 mg / mL, pD of the
solution was 4. Methodology for calculating pectin methylation and relative amount of 4,5-
dehydrogalacturonic acid have been previously described23 24
In vivo tumor studies
For primary tumor growth studies, B16F10 melanoma cells (2.5 x 105) were implanted in
the left flank of male C57/BL6 mice on day 0. ACP (0.5 mg/mouse) or NCP (0.5 mg/mouse)
were diluted in 100 uL PBS and injected s.c. in the left flank every third day starting on day 7
when the tumors had reached 100 mm3 in volume on day 7. Mice were sacrificed as required by
control tumor burden as on day 17. For experimental metastasis studies, B 1 6F 10 melanoma cells
were treated with 0.5% NCP (1 mg/mouse), 0.5% ACP (1 mg/mouse) or PBS for 30 minutes and
injected into the tail vein of C57/BL6 mice on day 0 similarly to previously described2 . On day
10, mice were sacrificed and lungs were excised and fixed in Bouin's solution. Metastatic
nodules were counted with the aid of a dissecting microscope.
Cell Viability
Cell viability was measured using the WST-1 reagent (Roche) according to
manufacturer's instructions. Briefly, B16F10 cells were plated in a 96 well plate so that they
would be ~50% confluent after 24 h. Cells were then treated with 1 mg/mL NCP, 1 mg/mL
ACP, or PBS control. After an additional 24 hours, cells were incubated with 10% WST-1
reagent and cell viability was quantified by absorbance at 450 nm.
Chemoinvasion through matrigel
A measure of chemoinvasion was performed similarly to that described previously.25
Briefly, Transwell inserts (Coming Inc., Corning, NY; 8 im pore size, 6.5 mm diameter) were
coated with 15 ptg of Matrigel (Becton Dickinson) and allowed to dry overnight in a sterile
laminar flow hood. Serum-deprived (0.1% FBS, overnight) B16F10 cells (2x10 5) were treated
with APC or NPC and were added to the top of inserts contained within growth medium (500 l)
supplemented with growth factor (40 ng/mL HGF) as a chemoattractant. After 40 h incubation,
non-invaded cells were removed using cotton swabs, and invaded cells were fixed using 2.5%
gluteraldehyde in PBS. Invaded cells were stained with crystal violet and counted with a Zeiss
Axiovert 200M microscope using 9 fields of view per insert.
Western blotting
Tissue samples were lysed in sample buffer and resolved on a 4-12% gradient SDS-
polyacrylamide-gel electrophoresis gel. The proteins were transferred to a nitrocellulose
membrane, blocked, and probed with primary antibodies to phospho-Akt (Ser473), phospho-
Akt(Thr308), phospho-PTEN(Ser380), and PTEN (Cell Signaling) as well as actin as a loading
control (Santa Cruz Biotechnology). Proteins were detected by chemiluminescence after
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incubation with the appropriate secondary horseradish peroxidase-labeled antibodies and
visualized with a Kodak 2000 gel-imaging system.
Cloning of human Gal-i and Gal-3
Gal-1 and Gal-3 were cloned using cDNA isolated from HUVECs. Cloning primers
containing NheI (5' end of the gene) and SalI (3' end of the gene) restriction sites are shown
below.
GAL-1
5'-ATATTGCTAGCATGGCTTGTGGTCTGGTCGCCAGCAACCTG-3'
5'-ATATTGTCGACTTAGTCAAAGGCCACACATTTGATCTTGAAGTC-3'
GAL-3
5'-ATATTGCTAGCATGGCAGACAATTTTTCGCTCCATGATGCG-3'
5'-ATATTGTCGACTTATATCATGGTATATGAAGCACTGGTGAG-3'
The vector (pET-28a(+)) was prepared with NheI and SalI followed by treatment with
CIP Alkaline Phosphatase (NEB) and purification with gel electrophoresis and gel extraction
(Qiagen). Ligation was performed with T4 DNA ligase (NEB) at 16 *C for 16 h. The galectin-
vector constructs were transformed into E. coli JM109. The pET-28a(+) constructs were
transformed into E. coli Rosetta2 (DE3) (Novagen) to overcome the unfavorable codon bias. The
cultures were grown in LB media containing kanamycin (100 pg/mL) and chloramphenicol (40
pg/mL) at 37 *C. In mid-log phase protein expression was induced with 1 mM IPTG for 18 h.
Induced E. coli Rosetta2 (DE3) cells were disrupted with sonication and the crude extract was rid
of debris by centrifugation (20000 rpm, 10 min, 4 *C) and purified with a Pharmacia 5 mL
HiTrap Chelating HP column using FPLC according to manufacturer's instructions. Proteins
were dialyzed through a 2000 MWCO membrane (Spectrum Laboratories Inc.) against
magnesium and calcium-free PBS and concentrated with 3000 MWCO Centriplus Centrifugal
Filter Devices (Millipore) at 4 *C. Histidine tags were removed with thrombin (Sigma)
treatment. Galectins were labeled with 5-(and6)carboxyfluorescein succinimidyl ester (CFSE)
from Fluka. Proteins at 0.5 mg /mL in 50% PBS buffer were incubated with 1.5 mg/mL CFSE
(in DMSO) in 9:1 ratio (v/v) for 2 h at RT. Proteins were dialyzed against 50% PBS through a
10000 MWCO membrane (Spectrum Laboratoris Inc.).
Gal-1 and Gal-3 interaction with pectin
Colorless polystyrene microspheres (3 pm diameter, Polysciences) were stably adsorbed
with either of the following: 50 pg lactose, 50 pg sucrose, 50 pg ACP, 50 pg NCP, 5 pg anti-Gal-
1 antibody or 5 pg anti-Gal-3 antibody. Adsorption of lactose, sucrose or pectin was carried out
by incubation with approximately 109 microspheres in 50 mM carbonate/bicarbonate buffer
(Sigma), pH 9.6, 37 *C for 3 h. Adsorption of antibodies was carried out by incubation with
approximately 109 microspheres in 0.1 M boric acid, pH 8.5, 37 "C for 2 h. Microspheres were
washed with water after either procedure. The treated microspheres were incubated with FITC-
labeled recombinant Gal-I and Gal-3 for 30 minutes on ice, and analyzed by flow cytometry in
the presence of increasing concentrations of lactose. Buffer-treated microspheres were used as
negative controls whereas anti-Gal-I and anti-Gal-3 treated microspheres were used as positive
controls for Gal-1 and Gal-3 binding, respectively.
FACS
Intracellular quantification of protein phosphorylation by flow cytometry was performed
similarly to previously described26 27 . Cells were treated with ACP (1 mg/mL), NCP (1 mg/mL),
or PBS control for 30 minutes in the presence of PBS, anti-Gal-1, or anti-Gal-3. Cells were
gently detached from the culture plate with 0.02% EDTA in PBS and immediately fixed with
2.5% v/v formaldehyde in PBS for 5 minutes on ice, washed once and permeabilized in PB
buffer (5% w/v BSA, 1% v/v rabbit serum, 0.1% w/v saponin, 10mM HEPES, 0.05% w/v NaN3
in PBS, pH 7.4) for 10 minutes on ice. The following primary antibodies were used (at 5 pg/mL
or diluted 1:100 in PBS containing 0.1% w/v BSA, 0.1% w/v saponin, 10 mM HEPES and
0.05% w/v NaN3, pH 7.4, 25 minutes on ice): phospho-Akt (Ser473), phospho-Akt(Thr308),
phospho-PDK1(Ser241), phospho-PTEN(Ser380), PTEN (Cell Signaling), phospho-
PI3K(Tyr5O8) (Santa Cruz Biotechnology), and rabbit IgG (Sigma, 5 E g/mL) as an isotype
control. Cells were washed and stained with fluorescein-conjugated anti-rabbit or anti-goat
antibodies (Invitrogen), 5 ptg/mL in PBS containing 0.1% w/v BSA, 0.1% w/v saponin, 10 mM
HEPES and 0.05% w/v NaN3, pH 7.4, 20 minutes on ice, followed by data acquisition on a
Beckman-Coulter Cell Lab Quanta SC MPL-enhanced flow cytometer. Means and coefficients
of variance produced by the Quanta AnalysisTM software were used for statistical evaluations.
PTEN knockdown
PTEN expression was knocked down using the SignalSilence PTEN siRNA kit (Cell
Signaling) according to manufacturer's instructions. Briefly, B16F10 cells were plated in a 96
well plate such that they would reach ~50% confluence after 24 hours. At this time, PTEN
expression was knocked down using targeted siRNA constructs with the supplied transfection
reagent overnight. Media was replaced and cells were treated with NCP (1 mg/mL), ACP (1
mg/mL) or PBS control for 30 minutes before harvesting for protein analysis. Intracellular flow
cytometry quantification of protein phosphorylation analysis was performed as described above.
2.4.3. Results and Discussion
Treatment of pectin with high pH or high temperature favors demethylation or beta-
elimination (fragmentation) of the pectin backbone, respectively. Beta-elimination, which also
leads to formation of 4,5-dehydro-galacturonic acid (dGalA), requires methylation of carboxyl
groups so is inhibited by a high pH/temperature ratio. The ratio of these two parameters can be
selected to achieve the desired amounts of methylation and defragmentation. We employed a
combination of high heat and base in a ratio to promote the formation of demethylated, soluble
pectin epitopes.
To quantify structural differences between NCP and ACP, we used capillary
electrophoresis (CE) and 1 H-NMR to analyze oligomeric composition as well as esterification of
GalA residues. CE analysis demonstrates that ACP contains proportionally reduced amounts of
neutral monosaccharides and increased amounts of GalA compared to NCP (Fig. 1 a). 1 H-NMR
spectrum of ACP indicates that -8% of GalA were converted to dGalA and that GalA was
NCP ACP
Rha % 2.0-3.0 1.0-2.0
Man % 1.0-2.0 0.5-1.5
GIc % 0.5-1.0 0.0-0.5
Xyl % 1.0-2.0 1.0-2.0
Ara % 8.0-14.0 3.0-9.0
Gal % 3.0-7.0 1.0-4.0
GaIA + dGalA % 70-85 80-95
dGaLA /Ga.A 0.0-0.02 0.07-0.10
Methyl d(GalA) 0.55-0.85 0.0-0.1
O-Acetyls / d(GaIA) 0.01 - 0.05 0.0 - 0.005
b
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Figure 1: Capillary electrophoresis and NMR analysis. (a) Composition of NCP and ACP as
determined by CE and 1 H-NMR. [Representative range] (b) Measurement of acetylation and
methylation of NCP. The 400 MHz 1H-NMR spectra of NCP at 80 *C after addition of 0.1 M
NaOD (final conc.) shows formation of methanol and Na-acetate. Amounts of methylation and
acetylation were calculated by comparing ratios of H-4 of GalA (4.44 ppm) and H-4 of dGalA
(5.78 ppm) with those of methanol (3.3 ppm) and Na-acetate (1.9 ppm)23. (c), (d): 400 MHz
1 H-NMR spectra of ACP and NCP demonstrating differences in amounts of dGalA and
methylation state. H-4 of GalA (4.44 ppm) and H-4 of dGalA (5.78 ppm) were used to
determine the relative amount of dGalA present.
[ppm]
free of methylation and acetylation (Fig. la,c). In contrast, NCP contained -70% methylated
GalA residues and dGalA was not present (Fig. 1 a,b,d). These results collectively indicate that
deesterification, fragmention, and enrichment for the galacturonic-acid containing
polysaccharide backbone are all major structural differences between ACP and NCP.
To determine the anti-tumor efficacy of ACP, we tested this compound in vitro and in
vivo using the well characterized, metastatic B 1 6F 10 mouse melanoma cell line. To assess the
role of ACP on primary tumor growth, B16F10 cells were implanted s.c. into C57/BL6 mouse
flanks. Treatment every third day with ACP inhibited tumor growth by -50% over the course of
our study compared to control and NCP treatment (Fig. 2a,b). In a separate experiment, ACP-
treated B16F1O cells were injected i.v. into C57/BL6 mice to assess the role of ACP on tumor
metastasis. ACP treatment inhibited the formation of lung metastatic nodules by -30%
compared to control and NCP treatment (Fig. 2c,d). ACP had no measurable effect on cell
viability under in vitro culture conditions (Fig. 2e), indicating a mechanism of activity
independent of direct tumor cell cytotoxicity. The in vivo anti-metastatic effect was
corroborated by in vitro experiments, with ACP exhibiting a dose-dependant inhibition of
B16F10 chemoinvasion through matrigel (Fig. 2f).
To identify potential therapeutic tumor targets for pectin, we assessed the relative binding
affinities of galectin-1 (Gal-1) and galectin-3 (Gal-3) for ACP and NCP. Gal-3 has previously
been implicated as a primary tumor target for modified pectins,13 however a recent study
demonstrated that modified pectins could still be effective against tumor cell lines lacking Gal-3
expression.7 This indicates the presence of as yet unknown pectin targets, so we also included in
our binding assays Gal-1, an additional galectin with an established role in tumor progression
and the potential to bind pectin residues. 14 To measure binding, ACP and NCP were adsorbed to
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Figure 2: Anti-tumor efficacy in vivo and in vitro. (a),(b) Comparing the effects of treatment
with NCP, ACP, and PBS control every third day on the growth of a B16F10 primary site
implant. (c),(d) Comparing the effects of treatment with ACP, NCP, and PBS control on the
number of B 16F 10 metastatic nodules on the lung in an experimental metastasis model. (e)
Measure of cell viability after treatment with NCP, ACP, and PBS control using WST-1 and
quantification by absorbance at 450 nm. (f) The effect of NCP, ACP, and PBS control on
B16F10 chemoinvasion through matrigel in response to HGF. Only the highest concentration of
NCP is pictured for comparison. Results are presented as means +/- s.e.m. *P < 0.05 vs. control.
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polymer beads and the adhesion of fluorescently labeled Gal-1 and Gal-3 was quantified by
FACS. Binding measurements were taken in the presence of increasing amounts of a lactose
inhibitor to distinguish relative binding affinity and the specificity of binding for the bioactive
carbohydrate recognition domains (CRDs) of the galectins. Binding to the CRDs of both Gal-I
and Gal-3 was significantly greater for ACP than for NCP (Fig. 3a), indicating that the ACP
activation protocol promotes the formation of galectin-binding structures.
To identify a potential mechanism of anti-tumor activity, we evaluated changes to the
intracellular AKT signaling pathway after treatment. Treatment of B 1 6F 10 cells with ACP
reduced AKT phosphorylation at both the Thr308 and Ser472 residues in contrast to treatment
with NCP and control (Fig. 3b). Reduced phosphorylation of AKT is known to promote a
diverse anti-tumor response, since AKT is a central regulator of a multitude of tumor processes
including growth, survival, and metabolism. 15'"6 We explored whether AKT dephosphorylation
is mediated by ACP binding to galectins. Tumor cells were treated with ACP in combination
with antibodies to Gal-I or Gal-3 to competitively inhibit ACP-galectin binding. Inhibited
binding to either galectin partially inhibited the dephosphorylation of AKT after ACP treatment,
indicating that binding to both galectins is involved in promoting an anti-tumor AKT-mediated
signaling cascade.
To further elucidate the anti-tumor mechanism, we investigated the involvement of two
regulators of AKT phosphorylation: PI3K and PTEN. PI3K is a classic therapeutic target that
promotes the phosphorylation of PIP2 to PIP3 which in turn acts to phosphorylate AKT. 16In
contrast PTEN, a recently identified therapeutic target, promotes the dephosphorylation of PIP3
to PIP2 which in turn acts to deposphorylate AKT.' 1 7 Western blotting demonstrated that
phosphorylation of PTEN at Ser385 was increased after ACP treatment, and this change was not
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Figure 3: Pathway analysis of anti-tumor activity. (a) Interaction of fluorescently labeled
galectin-1 and galectin-3 with NCP and ACP adsorbed to polystyrene beads. Sucrose and anti-
galectin antibodies were used as negative and positive controls, respectively. (b) Western blot
of the AKT signaling pathway after treatment with NCP, ACP, and PBS control. (c) Flow
cytometry analysis of phosphoprotein levels after inhibition of pectin treatment with anti-
galectin-1 and anti-galectin-3 antibodies. (d) Flow cytometry analysis of phosphoprotein levels
after NCP, ACP, iPI3K, and PBS control treatment of Bl6F10 cells that have had PTEN
knocked down by siRNA inhibition. Results are presented means and coefficients of variance
produced by the Quanta AnalysisTM software. MFI: Mean Fluorescence Intensity.
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present after treatment of cells with a P13K inhibitor (Fig. 3a). We next evaluated whether
PTEN was the initiator of AKT dephosphorylation after ACP treatment using siRNA silencing of
PTEN. ACP treatment no longer resulted in AKT dephosphorylation after PTEN silencing,
though the effect of the P13K inhibitor on the AKT pathway was unchanged (Fig. 3d). P13K
phosphorylation was also found to be inhibited by the P13K inhibitor and not by ACP treatment
(Fig. 3d). These results collectively demonstrate that PTEN activity is necessary for AKT
dephosphorylation after ACP treatment and that P13K is not a target for ACP.
2.4.4 Conclusion
We present here a standardized methodology for generating ACP using activation and
isolation conditions that promote the formation of soluble, bioactive pectin epitopes. We provide
an integrative approach to link pectin structure with anti-tumor efficacy and intracellular
mechanism of action. We demonstrate the first structure-function link that Gal-I and Gal-3
binding promotes an anti-tumor intracellular signaling cascade mediated by the
dephosphorylation of AKT. The identification of PTEN as an essential mediator of ACP's effect
on this pathway has direct implications for the potential translation of pectin as a clinical therapy.
Recent evidence has demonstrated that PTEN is also an essential mediator of activity for the
anti-tumor agent trastuzumab.9 Trastuzumab, an antibody to the erbB2 receptor, is a clinically
successful adjunct therapy for breast cancer that acts by disrupting AKT signaling. 19 In fact,
tumor expression of PTEN may be more indicative of therapeutic efficacy than over-expression
of the erbB2 receptor.9 Our results collectively suggest that ACP acts through a similar
mechanism, and may therefore have the potential to provide a safe, readily available alternative
adjunct therapy for patients with PTEN mediated pathology.
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3. Conclusions and Future Directions
3.1. Conclusions
The specific objectives of this thesis were as follows:
1. To exploit the pathophysiology of solid tumors and enhance combination chemotherapy
regimens by engineering novel nanoscale delivery vehicles termed 'nanocells.' (Chapter
2.1 and 2.2)
a. To assess the therapeutic benefit of this delivery platform.
b. To demonstrate that any increased therapeutic benefit is due to both the controlled
spatial and temporal release of the encapsulated agents, as indicated by the tumor
pathophysiology.
2. To develop new tools and strategies for optimizing nanocell formulations. (Chapter 2.3
and 2.4)
a. To develop a new computational model for drug release from nanoscale delivery
systems. A better understanding of nanoscale drug release will facilitate the
future optimization of nanocell spatio-temporal release profiles.
b. To generate and characterize a new set of carbohydrate-based anti-tumor agents
with low systemic toxicity. Anti-tumor carbohydrates may be used in nanocells
as reduced toxicity alternatives to traditional chemotherapeutic agents.
Objective 1 was met in chapter 2.1 and 2.2. Chapter 2.1 reported the disease-driven
engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to
solid tumors. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-
lipid envelope, and is preferentially taken up by the tumor. Several components of the nanocell
approach can facilitate future therapy in humans. First, the nuclear arrangement of cytotoxic
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agent-conjugated nanoparticle and the encapsulation of the anti-angiogenesis agent in the
surrounding phospholipid block-copolymer envelope enables temporal targeting of the tumor
vasculature, resulting in the intra-tumoral trapping of the nanoparticles. Second, the resultant
slow release and focal build-up of the cytotoxic agent within the tumor allows a prolonged
exposure and an increase in the apoptotic potential, which can overcome hypoxia-induced
reactive resistance. Third, although we show here a selective tumor uptake, we recognize that
these vehicles can be further specifically targeted to tumor vasculature by using probes that
recognize specific molecular signatures on the vasculature. Thus, the nanocell concept enables a
significant advance in cancer therapy over current approaches. This platform technology
supports the paradigm shift from a 'reductive' to an 'integrative' approach in cancer therapy.
Chapter 2.2 extended the application of nanoscale delivery systems and reported the first study
demonstrating the use of sterically stabilized lipid-encapsulated fluorescent quantum dots for
distinguishing normal and neoplastic vasculature. The delineation between the spatial
distribution of these formulations between tumor and normal vasculature creates the opportunity
to harness this approach in detection of solid tumors.
Objective 2 was met in Chapter 2.3 and 2.4. Chapter 2.3 reported a new computational
model for drug release from nanoscale delivery vehicles. Because all processes that influence
drug release are not yet quantitatively understood, there is value to the use of semi-empirical
computational models able to simulate multi-phase drug release profiles. Use of the model
presented here does not require knowledge of physical parameters such as polymer porosity,
drug solubility, and drug diffusivity which are often not available or can be difficult to measure.
Voxelation of the entire nanoparticle facilitates the extension of this platform to non-symmetrical
vehicle formulations as well as non-uniform drug and polymer distributions. Variation of the
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parameter K demonstrates the versatility of this model for simulating release of hydrophilic,
hydrophobic, and polymer-conjugated drugs. This model was intended as a proof of principle,
however in the future emerging mechanistic understandings of phenomenon influencing
nanoparticle drug release may be incorporated to further increase accuracy and strengthen
predictive power. Chapter 2.4 reported the generation and characterization of new anti-tumor
pectin epitopes. We provided an integrative approach to link pectin structure with anti-tumor
efficacy and intracellular mechanism of action. We demonstrated the first structure-function link
that Gal- 1 and Gal-3 binding promotes an anti-tumor intracellular signaling cascade mediated by
the dephosphorylation of AKT. The identification of PTEN as an essential mediator of ACP's
effect on this pathway has direct implications for the potential translation of pectin as a clinical
therapy. The reduced toxicity and polymeric nature of ACP make it a good alternative to
traditional chemotherapeutic agents in future nanocell formulations.
3.2. Future Directions
The spatio-temporal delivery platform of the nanocell and the techniques for the
development and analysis of carbohydrate-based chemotherapeutic agents have ready extension
to a number of therapeutic applications. We conclude by discussing two that are currently under
exploration as future directions of this work.
3.2.1. Extending the nanocell platform
Solid tumors are suitable targets for nanocell therapy due to their pathophysiology as
discussed in detail in this work. In the future, the nanocell delivery strategy could also be
applied to any disease with an angiogenic or multi-compartmental basis. For proof of principle,
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we present asthma as a model pathology for future nanocell treatment strategies. The National
Heart, Lung, and Blood Institute includes the following features as integral to the definition of
asthma: recurrent episodes of respiratory symptoms, variable airflow obstruction that may be
reversible, airway hyperreactivity, and chronic airway inflammation'. Asthma is well suited for
treatment by a nanocell-like therapy due to the multicompartmental nature of this disease,
especially as these components act on significantly different time scales.
Asthma occurs after initial sensitization to inhaled antigens which stimulate induction of
Th2-type T cells which release cytokines including IL-4 and IL-52. These released cytokines
stimulate B cells to produce IgE, mast cells to grow, and eosinophils to grow and activate. The
IgE-mediated reaction to these inhaled allergens results in an acute and late-phase response.
During the acute response, crosslinking of IgE on the mucosal surface results in the release of
chemical mediators which open the mucosal tight-junctions and enhance penetration of antigen.
Further, direct stimulation of subepithelial vagal receptors provokes bronchoconstriction through
central and local reflexes. This acute or immediate phase response occurs within minutes of
stimulation and consists of bronchoconstriction, edema, mucus secretion, and potentially
hypotension.
The same mediators involved in the acute phase response also recruit other leukocytes
including neutrophils and monocytes, lymphocytes, basophils, and eosinophils. The major basic
protein of eosinophils in turn causes epithelial damage and airway constriction. This late phase
response starts 4 to 8 hours after stimulation and may persist for 12 to 24 hours or more. In fact,
inflammatory cells chronically present in asthmatics may release further mediators which
enhance the severity of the late phase response. Long-term inflammatory remodeling and
fibrosis remains one of the most severe symptoms of chronic asthmatics.
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Currently the acute and long-term phases are treated with B2 agonists and corticosteroids
respectively, however controversy still surrounds the proper use of both. Prior to the recognition
of asthma as an inflammatory disease, B2 agonists were often the sole therapy for asthmatics.
Recent reports have however raised concern regarding mortality and desensitization with this
treatment3. There is conflicting evidence, however, whether excessive or regular use of p-
adrenergic bronchodilators can actually worsen asthma, perhaps contributing to morbidity and
mortality4' 5. Corticosteroids have now become the first line defense in almost all patients with
persistent asthma, though there is continued debate regarding the dosing regimens of inhaled
steroids. Several studies with long term follow-up indicate that corticosteroids do not cure
asthma, and cessation of therapy often results in swift relapse. Some studies suggest that in stable
asthmatics less-frequent dosing may be equally effective . Data also supports the often
recommended combination therapy of corticosteroids and long-acting B2 agonists. These
patients still require a separate short acting B2 agonist for acute asthmatic attacks.
Currently treatment for asthma is directed by a series of expert practice guidelines and
widespread dissemination. However, the Cleveland Clinic points out that most of these
guidelines are not truly evidence based and represent an expert opinion. As asthma research is a
rapidly evolving area and new therapeutics are anticipated, these guidelines are expected to be
revised periodically. The hope is that as controlled studies become available, expert dogma will
be replaced by data6 .
Towards this goal, we are exploring a pathophysiology-driven approach to asthma
therapy. This therapy would utilize a nanocell-like delivery vehicle capable of delivering a short
acting B2 agonist quickly to a patient in acute distress with the subsequent sustained release of a
corticosteroid. This nanocell formulation would have the benefits of less frequent dosing and
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better patient compliance. Less frequent dosing would decrease the likelihood of steroid
desensitization, and patient compliance is an issue in asthma therapy due to "steroid phobia."
The sustained release platform would allow smaller corticosteroid drug concentrations, and the
delivery of this agent directly after B2 agonist action may allow greater penetration within the
lung tissue. The cost of production of this dual-release vehicle may also be balanced by the
reduced cost of smaller drug amounts.
3.2.2. Extending structure-function analysis of carbohydrate-based therapies
We have developed in this study tools and strategies for the elucidation of complex
structure-function relationships for pectin-based chemotherapeutics. These techniques are
readily extendable to other complex carbohydrate-based chemotherapeutic agents which would
greatly benefit from similar analysis. We present heparan sulfate glycosaminoglycans
(HSGAGs) as a model system for future exploration. HSGAGs are linear polysaccharides with a
great deal of structural complexity found both on the cell surface and within the extracellular
matrix (ECM). Recent progress in understanding the biosynthetic regulation of these molecules
combined with powerful new tools for their structural and functional characterization has led to a
virtual explosion in the number of biological processes in which HSGAGs have been implicated.
Some major processes in which HSGAGs appear to play a key regulatory role include
development7, growth factor signaling8 , viral and bacterial invasion9 , wound healing'0 , and
tumor progression"
Exploration into the structure/function relationship of HSGAGs for modulating biological
processes has long been hindered by difficulties in their structural characterization and
sequencing. The basic disaccharide repeat of the HSGAG polysaccharide chain consists of a
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hexuronic acid linked 1,4 to a hexosamine with four potential sites of chemical modification.
Together the four different modifications combined with the potential for either the iduronic or
glucuronic acid isomer give rise to 32 different plausible disaccharide units12 . This can be
contrasted with the 20 amino acids for proteins and the 4 bases for DNA. In a single
octassaccharide, there are theoretically more than a million potential structures. Also, unlike the
biosynthesis of DNA and protein, the biosynthesis of glycosaminoglycans is not template-based,
and so the sequencing and amplification of HSGAGs is not amenable to the same technologies
used with these biopolymers.
The information rich carbohydrate backbone of heparan sulfate consists of alternating
hexuronic acid (D-glucuronic acid (GlcA) or L-iduronic acid (IdoA)) linked 1,4 to D-
glucosamine (GlcN) units. These polysaccharides are attached to their core protein via
tetrasaccharide linkage regions consisting of -GcA-Gal-Gal-Xyl-Ser residues(for review see13).
After the initial formation of this tetrasaccharide, the alternating addition of GlcA and GlcNAc
from their UDP-sugar nucleotide precursors forms a repeating 1,4-linked disaccharide chain.
The disaccharide chain is further modified either concomitantly or independently and
sequentially by a series of sulfotransferases" I, of which N-deacetylase-N-sulfotransferase
(NDST), the 2-0 (HS2ST), 3-0 (HS3ST), and 6-0 (HS6ST) heparan sulfate sulfotransferases are
key players (Figure 1-1). Several tissue and substrate specific isoforms of each of these
sulfotransferases have been discovered, signifying a further level of complexity in the
biosynthesis of heparan sulfate(for review see 14 ).
One recent study from our laboratory has demonstrated an effective methodology for
sequencing heparin oligosaccharides utilizing a combined capillary electophoresis-mass
spectrometry approach. In this study, exhaustive digestion of heparin oligosaccharides with
111
heparinases decomposes heparin into its disaccharide building blocks which are then amenable to
analysis by capillary electrophoresis (CE). Matrix assisted laser desorption/ionization mass
spectrometry (MALDI-MS) further supplies information on the molecular mass and possible
combinations of the disaccharide units. Partial digestion using the different substrate
specificities of heparinase I, II, and III, with subsequent MALDI-MS analysis gives further
structural information that may be used in a stepwise fashion to determine the overall
oligosaccharide sequence.
The ability to isolate and characterize HSGAG fragments combined with our now
extensive understanding of the biosynthesis of HSGAGs has for the first time provided the tools
to begin to elucidate the mechanisms of HSGAG regulation in important biological processes
and pathologies. Recent developments in HSGAG regulation of cancer progression provide an
urgent application for these technologies.
Many of the events associated with tumor growth and metastasis are directly influenced
by interactions between malignant cells and their ECM. Due to the key regulatory roles of
HSGAGs in processes that occur at the cell surface-ECM interface, it is not surprising that a
large body of evidence has been found implicating HSGAG involvement at almost all levels of
cancer development and progression (for recent reviews", 1"'"). A recent study from our lab has
for the first time, however, demonstrated a direct link between the composition of a tumor's cell
surface HSGAG coat and its potential for malignancy' 7 . This study made use of the heparan
sulfate cleaving enzymes heparinase I and heparinase III, which have distinct and opposing
heparan sulfate substrate specificities, as tools for analyzing tumor cells with different cell
surface compositions of HSGAGs. It was discovered that tumor cells treated with heparinase III
(with cleavage at undersulated HS regions) showed significantly less ability to colonize to lungs
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than cells treated with heparinase I (with cleavage at highly sulfated HS regions) or control cells.
Further, fragments from tumor cells exposed to heparinase III inhibited the growth of primary
tumor in vivo, while fragments from tumor cells exposed to heparinase I had the opposite effect.
While this study links HSGAG sulfation with tumor progression, it is not clear how tumor cells
biosynthetically regulate their HSGAG sulfation in vivo, or what heparan sulfate differential
sulfation patterning is most relevant in tumor progression.
The contribution of HSGAG biosynthetic enzymes to tumorigenesis has already been
demonstrated with the discovery of the tumor suppressor genes EXTI and EXT218. These
genes have been implicated in the formation of chondrosarcomas and other sporadic cancers, and
encode the enzyme GlcA/GlcNAc transferase which is required for heparan sulfate chain
elongation and synthesis19. The contribution of other enzymes involved in HSGAG biosynthesis
to tumor progression has not yet been elucidated. We propose here an approach to further
elucidate the role of HSGAG differential sulfation in tumor development by altering the
expression of three biosynthetic sulfotransferases, HS2ST, HS6ST, and HS3ST, via the use of
mRNA and siRNA knockdown constructs.
Modulation of a target gene's activity may be accomplished both at the
DNA and mRNA levels. The most commonly used DNA-level approach for gene targeting is
gene knockout by homologous recombination. Homologous recombination involves the "knock-
out" of a gene through physical disruption of the targeted gene resulting from crossover events
occuring during cell division between the targeting vector and the selected gene.2 0 While
effective, this technique is hampered by its inefficiency, expense, and limited use in animal
models for embryonic lethal knockouts. Other gene-level disruption techniques include the use
of synthetic oligodeoxynucleotides (ODNs) capable of hybridizing double-stranded DNA
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forming a triple-stranded helix and preventing subsequent transcription events2 1, as well as the
use of specific nucleic acid sequences to act as decoys for transcription factors 22. The former is
limited by access to DNA compacted within the chromosome structure, and the latter by the lack
of single-gene transcription factors.
mRNA-level gene silencing approaches involve the destabilization of target mRNA,
thereby preventing synthesis of the target protein. While anti-gene targeting approaches are in
theory more advantageous from a stoichiometric point of view, mRNA itself is more accessible
and mRNA disruption allows for greater control over the degree of gene disruption, as well as
for temporal regulation. A recently developed method for mRNA disruption involves the use of
RNA interference (RNAi) or post-transcriptional gene silencing23 . RNAi involves the use of
double-stranded RNA transcripts which lead to diminshed levels of complementary endogenous
mRNA after introduction into the cell. RNAi has been well demonstrated in C. elegans and
drosophila, and there is currently a great deal of study into understanding the mechanism of
action and achieving a similar effect in mammalian systems .
A well established technique for regulating gene expression at the mRNA level is the use
of antisense RNA or DNA. Antisense RNA involves the introduction of vector-generated
mRNA complementary to regions of the target mRNA strand. These complementary mRNA
strands form a double helix within the cell resulting in disruption of subsequent translation.
Naturally occuring antisense RNA in higher eukaryotes has been well documented (for review
see 26). Antisense transcripts are usually transcribed from the same locus as the sense RNA, but
in the opposite direction with overlap over the region of sense transcription. Studies of bFGF
during embryogenesis have demonstrated a reciprocal relationship between sense and antisense
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transcripts , and the natural expression of an antisense transcript to eIF-2a in peripheral blood T
cells is thought to play a role in regulating gene expression2.
The mechanism of antisense inhibition is not well understood in the case of both naturally
occuring and artificially introduced antisense mRNA, and it appears to be different for each case
involved. In general, antisense mRNA is thought to block gene expression by hybridizing to the
target mRNA resulting in the formation of a double helix. This process may occur at any point
after transcription and before the initiation of translation. Therefor possible mechanisms range
from disruption of post-transcriptional splicing, inhibition of nuclear transport, destabilization of
the transcript, and disruption of translation(for review see 29). As such, difficulties arise in
rationally designing synthetic antisense mRNA to achieve a significant gene knockdown. We
propose to design antisense mRNA to regions of the target sulfotransferase mRNA with the goal
of obtaining multiple levels of gene knockdown. The 5'UTR and two regions of the 3' UTR
could be targeted as these segments have long been naturally implicated for playing a significant
role in translation initiation and termination, transcript stability, and nuclear transport.
mRNA knockdown of specific sulfotransferase enzyme transcripts would result in tumor
HSGAGs with controlled sulfation profiles suitable for assessing relationships between fine
structure and tumorigenicity using the tools and techniques developed in this work for pectin-
based therapies. HSGAGs, like pectin, represent a potential source for natural, readily available,
cost-effective, and low toxicity carbohydrate-based chemotherapeutic alternatives.
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